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Abstract 
 Proteins are inherently dynamic. Virtually all of the processes that underlie biological 
activity, including binding partner recognition, catalysis and allostery among many others, 
require transient adoption of specific high energy conformations. While many proteins contain 
highly dynamic regions or Intrinsically Disordered Domains (IDDs), Intrinsically Disordered 
Proteins (IDPs) are free of well-defined structural features altogether. These domains/proteins 
play integral roles in a wide variety of biological processes, but are often associated with 
neurodegenerative disease and cancer. Hence it is crucial to study these biomacromolecules to 
understand the structural underpinnings of their biological functions as well as the factors that 
drive disease pathology. However, many of the current high resolution structural techniques (like 
X-ray crystallography and NMR) are not feasible for such studies because of their reliance on the 
presence of a well-defined ‘native’ conformation. An emerging structure labeling technique 
called Time Resolved-Hydrogen Deuterium Exchange (TR-HDX) can offer an alternative 
strategy. In this approach, structure-dependent hydrogen/deuterium labelling is measured on the 
millisecond timescale, providing an exquisitely sensitive picture of the weak hydrogen bonding 
networks that impart ‘residual structure’ in IDDs and IDPs. In this work, TR-HDX was 
implemented onto microfluidic chip to achieve solution phase site-specific analysis of the 
structures and dynamics of p53 N-terminal transactivation domain and tau protein. Gas-phase 
TR-HDX was also implemented to study gas-phase protein structures that become populated 
during Differential Mobility Spectrometry (DMS) ion mobility analyses. Critical advances 
include the discovery and characterization of an amyloidogenic tau intermediate that may 
underlie Alzheimer’s disease pathology, a dynamics-based model for recruitment of co-factors to 
cancer protein p53 upon phosphorylation, a detailed account of how a set of anti-amyloid drug 
candidates affect tau structure and dynamics, and development of a method to predict solution-
phase protein stability from DMS-HDX measurements.  
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Chapter 1 
Introduction 
1.1 Mass Spectrometry 
Mass spectrometry (MS) has existed for more than a hundred years and has proven to be 
a powerful analytical technique that is capable of measuring ionised atomic and molecular 
masses1,2. Even at its infancy, there was motivation to advance this nascent technology due to its 
high degree of selectivity. It was suggested by Wilhelm Wien’s discovery that positively charged 
particles can be deflected using a strong magnetic field, which gave MS its start. However, it was 
J.J. Thompson who spearheaded this technology when he discovered two different neon isotopes 
using electric and magnetic fields1,2. Ionization is a prerequisite for transferring analytes into the 
gas-phase for accurate mass determination. Since the advent of soft ionization techniques, 
ElectroSpray Ionization (ESI) and Matrix-Assisted Laser Desorption Ionization (MALDI), the 
analytical field in MS has developed rapidly and paved the way to study large biomolecules such 
as proteins, and large macromolecular protein complexes such as viruses3–5.  
 
1.1.1 ElectroSpray Ionization (ESI) 
  ESI, one of the two soft ionization techniques, is widely adopted in the field of life 
sciences. Although John Fenn won and shared the Nobel Prize for his contribution in the 
ionization technique, it was Malcolm Dole and coworkers who first discovered the process in the 
1960s. Generally, the ESI process is initiated by applying a high voltage (2-6kV) to the tip of a 
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thin metal stainless steel capillary containing flowing analyte solution at low flow rates (Figure 
1.1)6,7. There are two modes of operation, positive and negative. For example, in positive ion 
mode, an electrochemical reaction of the solution (water oxidation) occurs causing electrons to 
flow to the outer walls of the capillary and the accumulation of positively charged ions in 
solution. The positive potential generated will repel and drive positively charged analytes 
towards the end of the capillary forming a conical structure called Taylor cone8. The strong 
electric field will disperse the liquid solution in the Taylor cone into smaller highly charged 
parent droplet aerosols due to strong coulombic repulsion6,7.  As the droplets migrate towards the 
mass spectrometer, this repulsion force passes the Rayleigh limit which will eventually generate 
progeny droplets resulting from jet fission7,9. This process occurs numerous times during the 
transit period with the analytes usually containing numerous charges. Concomitantly, dry 
nitrogen sheath gas is flown coaxially around the capillary to aid in nebulisation. This helps with 
the desolvation process and reduces the degree of cluster ion formation7. 
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Figure 1.1. A representation of the electrospray ionization process in positive ion mode.  
High electric field applied to the ESI metal capillary containing analyte solution causes the 
formation of the Taylor cone. This results in the ejection of the positively charged parent ions 
due to overpowering of the columbic force while the negatively charged ions align at the walls of 
the capillary. Subsequently, these parent ions fly towards the negatively charged curtain plate of 
the mass spectrometer. During the transit, there is an interplay between solvent evaporation and 
the columbic repulsion force. When the columbic forces are greater than the surface tension of 
the droplets, parent ions undergo a jet fission process giving rise to smaller progeny droplets. 
This jet fission process occurs numerous times and at an increasingly faster rate due to smaller 
droplet size until the charged analytes are transferred into the mass spectrometer. 
 
1.1.2 Quadrupole Time-of-Flight (QToF) Mass Spectrometers 
QToF mass spectrometers are powerful robust instruments that are widely utilised in the 
analytical community mainly due to its high sensitivity and high mass accuracy10. Conventional 
QToF instruments usually consist of quadrupole 0 (Q0) for focusing of ions as they enter the 
mass spectrometer, Q1 for mass selection and transmission, Q2 for parent ion fragmentation in 
the collision cell, ToF for mass separation, and a detector component  (Figure 1.2)10. Of course, 
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the above describes one of the earliest designs as well as current conventional models and 
currently there many variants with additional features. For example, Waters G1 and G2S models 
use an ion guide and a stepwave ion guide, respectively, in place of Q0 and also contains an 
additional separation dimension called the ion mobility cell11,12.  
Briefly, Q0 and Q2 operate under radio frequency (rf) mode and is normally maintained 
in the range of 10-50 mTorr10. This rf field provides radial confinement and collisional cooling 
resulting in better focusing of the ions. Ions are focused in Q0 as a concentrated beam as it enters 
the mass spectrometer to the Q1 chamber10. Q1 acts as a mass filter and is operated under both rf 
and dc voltages to allow certain mass to charge (m/z) transmission window10. Q1 is normally 
maintained at a low pressure of 10-5 torr to avoid ion diffusion and fragmentation of the parent 
ions10. If MS/MS or fragmentation mode is operated following the transmission, the ions are 
accelerated into the pressurised Q2 chamber where collisional induced dissociation (CID) occurs 
with the bath gas (typically N2), giving rise to product ions
10. Upon exiting the final quadrupole, 
the ions (product ions if MS/MS is operated) are then reaccelerated and focused by ion optics 
into the ToF analyser (Figure 1.2)10. Here, the ion modulator pulses the incoming ions (several 
kilohertz) orthogonal to their trajectory where mass separation occurs10. For detection, variants 
of electron multipliers are used such as microchannel plates to amplify the signal10. Classically, 
mass spectra are recorded with time-to-digital converters (TDC), however, with advancing 
technology, the current systems now commonly use analog-to-digital converters (ADC). 
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Figure 1.2. Schematic representation of a QToF mass spectrometer. Electrosprayed gas-
phase ions are cooled and focused at Q0 quadrupole upon entering the orifice of the mass 
spectrometer and are m/z selected at Q1 using rf field. Q2 is operated at higher pressure 
containing neutral particles such as nitrogen and provides a collision chamber for CID if desired. 
Ions exiting Q2 are then refocused into a beam by ion optics entering the ToF analyser. The ion 
modulator then pulses ions orthogonal to their original trajectory into a high vacuum space where 
mass separation occurs. Ions are deflected at the ion mirror for enhanced separation which are 
then detected using ToF detector such as multichannel plate detectors as shown. Adapted from 
Chernushevich et al10. 
 
1.2 Ion Mobility Spectrometry- Brief Introduction 
Ion Mobility Spectrometry (IMS) is a powerful analytical technique that can separate gas-
phase ions based on their size and shape13. Thus far, three main IMS techniques exist: drift time 
IMS (DTIMS), travelling wave IMS (TWIMS), and field asymmetric IMS (FAIMS) or 
differential mobility spectrometry (DMS)13. IMS coupled to MS can significantly improve 
selectivity, speed, and limit of detection13. The additional separation dimension along with liquid 
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chromatography-MS (LC-MS) or MS alone can improve the selectivity process especially in 
isolating isobaric species and different ion conformations14,15. IMS can also perform high 
throughput analysis by separating ions on the millisecond timescale as opposed to seconds 
timescale in conventional chromatography, enhancing the speed of analysis13. A lower limit of 
detection can be achieved by filtering out background noise during the separation process16. The 
next two paragraphs will briefly introduce DTIMS. TWIMS and DMS will be discussed in the 
following sections. 
DTIMS represents the first IMS technique, where low uniform electric fields of 5-100V 
are applied to propel ions in a drift tube filled with drift gas, typically He (Figure 1.3)13,17. The 
time for an ion to traverse through the tube can be correlated with the ion’s rotational collisional 
cross section (CCS) where ions with smaller CCS will travel faster than that of bigger CCS due 
to fewer collisions or interactions with the drift gas13,17. The reduced mobility coefficient, k0 can 
be calculated using the following equation18: 
𝑘0 = (
𝐿2
𝑡𝐷𝑉
) (
273.15
𝑇
) (
𝑝
760
) (1) 
where L refers to the drift tube length, tD is the drift time, V is the applied voltage across the drift 
cell, T corresponds to temperature in kelvin, and p is the gas pressure in torr. Upon finding k0, 
CCS can then be determined using the Mason-Schamp equation18: 
𝛺 =
3𝑧ⅇ
16𝑁
(
2𝜋
µ𝑘𝐵𝑇
)
1
2⁄
(
1
𝑘0
)  (2) 
where z is the charge of the ion, e is the elementary charge, µ is the reduced mass of the ion-
neutral pair, and kB is the Boltzmann constant. 
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 DTIMS offers several advantages over the other two IMS techniques such as high 
resolving power (R>100), however, due to its gated feature (this also applies to TWIMS), only a 
limited percentage of the total ions are detected13. Although DTIMS is the earliest version of 
IMS, it is still widely utilized for accurate gas-phase CCS determination of macromolecules such 
as peptides and proteins and correlates well compared to other structural biophysical techniques 
such as X-ray crystallography and Nuclear Magnetic Resonance (NMR)13. 
 
Figure 1.3. A schematic representation of DTIMS. Low electric field (5-100V) is applied 
along the same direction as the ion path and drift gas is flown in the opposition direction. Ions 
are then separated by interaction with the drift gas. Hence ions with bigger CCS are slowed 
down compared to smaller CCS due to more frequent interactions with the drift gas. Adapted 
from Lanucara et al13. 
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1.2.1 IMS- Travelling-Wave Ion Mobility Spectrometry 
 Similar to DTIMS, TWIMS also operates at low fields in the presence of neutral gas such 
as helium or nitrogen, however there are a few differences in operation as shown in Figure 1.4. 
TWIMS is comprised of a series of stacked ring ion guides where alternating phases of rf voltage 
are applied to adjacent rings such that ions are radially confined12. In addition, a direct current 
(DC) voltage is superimposed to this rf voltage, creating a “wave” such that ions can surf axially 
on this wave. As a result, ions with higher mobility can surf over the wave effectively reducing 
their transit time whereas ions with lower mobility cannot due to “rollover” effect12. TWIMS has 
also been useful in CCS determination (requires prior calibration with known CCSs) and is being 
increasingly adopted in the field of structural biology. Robinson and colleagues were one of the 
first groups to study large protein complexes using this method19. For example, they transferred a 
large protein complex of 90kDa called trp RNA binding attenuation protein (TRAP) into the gas-
phase and demonstrated that its structural topology remained intact. Furthermore, its determined 
CCS was in close agreement with data generated from X-ray crystallography. Later on, Heck and 
colleagues pushed the boundary and studied intact hepatitis B virus capsids (4MDa)20.  
 
 
 
 
 
9 
 
 
Figure 1.4. A schematic representation of TWIMS. Application of alternating rf voltage along 
with superimposed DC voltage to a series of stacked ring ion guides results in travelling wave 
voltage allowing for ions to surf and separate on these travelling waves. Ions with higher 
mobility are able to surf over the wave whereas ions with lower mobility tend to roll back, thus 
increasing the transit time in the tube. Ion separation can be optimized by adjusting the wave 
height and speed. Adapted from Lanucara et al13. 
 
1.2.2 IMS- Differential Mobility Spectrometry 
DMS and its analogue, FAIMS, is an emerging bioanalytical technique that can act as an 
orthogonal separation dimension to existing LC-MS or MS for enhanced selectivity and 
sensitivity21. Originally developed to detect illegal and explosive substances, it is now becoming 
a common tool in structural biology for analysis of proteins’ three-dimensional structure and its 
conformational dynamics, at least for small proteins (10kDa>)13,22–25. Unlike conventional IMS, 
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where ion separation is dependent on the drift time through a neutral gas and under low electric 
field strength, in DMS, ions are 'pre-selected' for transfer into the mass spectrometer based on the 
difference between their high-field (~30,000 V cm-1) and low-field (~1,000 V cm-1) mobilities, 
K 21,26. To do this, an asymmetric rf voltage (Separation Voltage, SV) is applied perpendicular 
to the flow of ions, resulting in a net lateral displacement and an 'unstable' trajectory which will 
eventually lead to and discharge at one of the electrodes. Another sweeping DC offset potential 
(Compensation Voltage, CV or CoV) is applied to successfully transmit ions of different K  
(Figure 1.5)21,26. The mobility of an ion in these electric fields can therefore be described by the 
following equation: 
𝑘ℎ(𝐸) =  𝑘𝑜[1 + 𝑓(𝐸)] (3) 
where 𝑘ℎ, 𝑘𝑜 is the mobility in high and low field respectively and 𝑓(𝐸) is the ion mobility 
dependent on electric field strength. In DMS, there are three types of ion behaviours: type A, 
type B, and type C. Type A ions exhibit an increase in mobility with increasing fields (clustering 
effect). Type B ions exhibit an initial increase followed by a decrease in mobility as a function of 
electric field (polarizing effect). Type C ions exhibit a decrease in mobility as a function of 
increasing field strength (rigid sphere model).  
A typical DMS setup consists of two parallel plates where the high/low voltages are 
applied with two gas inlets: a transport gas (typically N2 and other modifier gases) at the entrance 
of DMS for separation enhancement, and a resolving gas at the interface between the exit of 
DMS and MS entrance for resolution enhancement21,26. One attractive characteristic of this 
approach is that the separation is principally dependent on the parameter, K, hence interactions 
with different types of transport gases within the DMS instrument can have a substantial impact 
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on K27,28. This can be advantageous where optimization of the transport gas mix (i.e., the 
modifier gas) can allow for high-resolution separation of isobaric analytes and even of species 
with identical CCS areas21,27. For larger proteins (>15kDa) with significant molecular dipoles, a 
particular problem is field-induced alignment which results in bimodal CV profiles for unimodal 
structural distributions29. As a result, there has been little effort to apply DMS to large 
biomolecules and no success in linking gas-phase structural insights acquired by DMS to the 
solution phase conformational ensembles of proteins29,30. 
 
Figure 1.5. Schematic diagram of two ions travelling in a planar DMS cell. Top plot 
illustrates the field asymmetric wave pulse sequence. Briefly, the lower plate is held at a ground 
potential whereas asymmetric waveform is applied by the upper plate and net sum of the high 
and low field voltage is 0 as shown by the plot. This results in a short, high field pulse followed 
by a longer low field portion resulting in a net trajectory of ions towards the mass spectrometer. 
Ions are then separated by their K (mobility difference in high- vs. low- field). The red ion’s 
high field mobility increases compared to its low field mobility hence causing it to be more 
sensitive at high fields compared to the blue ion. Adapted from Lanucara et al13. 
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1.2.2.1 IMS- DMS, Modifier Gas Effects 
As mentioned above, adding different modifier gases in the transport gas line can have 
beneficial effects in separation and resolution31. Inert and/or polar modifiers can be used in the 
transport gas31,32. When inert gas such as helium or nitrogen is implemented, ion and modifier 
gas interaction is predominantly dictated by the rigid sphere model32. However, when polar 
modifiers such as acetonitrile, methanol, isopropanol, acetone etc. are used, the interaction of 
modifier gases with analytes in the DMS chamber can be explained using the dynamic 
cluster/decluster model31,32. The model suggests that during the transit of ions in low rf field, 
modifier gas molecules can form clusters with the analytes due to low energetic conditions and 
these complexes are then declustered during the high rf field transit32. Hence over a series of 
these high/low field cycles, the analytes and modifier gases are undergoing dynamic clustering 
and declustering, affecting K31,32. All polar modifiers have the potential to induce this 
mechanism with different efficiencies. Hence with proper optimization, this technique can 
provide a powerful orthogonal separation dimension to the existing MS platform. For example, 
Figure 1.6 shows the DMS ionogram of 140 different small molecule compounds. SV was 
constant and the CV was ramped from -100V to 20V32.  Without any modifier gas, most peaks 
were clustered in the narrow CV window (~20V range) and were not separated. However, upon 
addition of 1.5% isopropanol as a modifier gas, the separation of the compounds was improved 
drastically encompassing a CV range of ~100V32.  
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Figure 1.6. Effect of DMS separation upon addition of modifier gas. Top/bottom spectra 
represents DMS ionogram of 140 compounds without/with any modifier gas respectively. In the 
absence of any modifier gas, the separation capabilities were poor with the majority of the peaks 
clustered in a narrow Compensation Voltage (CV or CoV) window. Upon addition of modifier 
gas, 1.5% isopropanol, the separation was drastically improved spanning over a 3-fold increase 
in the CV region. Adapted from Schneider et al32. 
 
1.2.2.2 IMS- Differential Mobility Spectrometry Hydrogen Deuterium 
Exchange (DMS-HDX). 
Gas-phase HDX is a structure-dependent labeling technique in which hydroxyl, thiol, 
amine and amide hydrogens undergo exchange with deuterons from the surrounding gas28. 
Although, the reaction mechanism in the gas-phase is not as well understood as solution phase 
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HDX, it is still viewed as a sensitive probe of gas-phase structure that can be reflected to solution 
phase structures33. Gas-phase HDX in conjunction with a variant of the DMS setup, FAIMS, has 
been performed previously to provide a simultaneous, orthogonal characterization of protein 
structure; however the resulting profiles were difficult to interpret in the context of solution 
structure24,29. For instance, adjacent charge states from the same solution-structure 
subpopulations exhibited wildly different DMS-HDX profiles22,34. Moreover, the profiles 
displayed a multitude of co-populated conformations with substantially different CVs which 
suggests that much of the conformational heterogeneity was generated during DMS 
separation22,24,34. Thus, DMS-HDX was demonstrated as a useful tool for investigating different 
gas-phase conformers, but also shown to have poor correlation to solution phase structure. 
 
1.3 Liquid Chromatography (LC) 
 LC is an important analytical separation technique and still present as a major workhorse 
in many analytical applications such as pharmaceutical, environmental, and clinical settings35. It 
is a quantitative and qualitative technique that is commonly used to separate complex mixtures 
for purification, identification, and quantification35. Typically, LC involves a column with 
packing material referred to as the stationary phase, a pump to move pressurised mobile phase(s) 
through the column and a detector that displays the time at which analytes elute called retention 
time35,36. Retention times vary depending on the nature of the interaction of the analyte and the 
column (chemical or physical interaction) as well as the solvents used35. Normally, there are five 
types of LC: normal phase, reverse phase, size exclusion, ion exchange, and bioaffinity 
chromography.  
 
 
15 
 
Normal phase LC (NPLC) uses a polar stationary phase (amino functional group 
moieties) and non-polar solvents (hexane) as the mobile phase37. Hence polar analytes are 
retained by the polar stationary phase and the adsorption interaction increases with more polar 
analytes37. NPLC is useful in separating hydrophobic molecules such as polysaccharides38.  
Reverse-phase LC (RPLC), unlike NPLC, uses a non-polar stationary phase (C20, C18, C4) 
and a polar mobile phase (acetonitrile, water, methanol) which operates via hydrophobic 
interactions between the analytes and the stationary phase39. A typical application of RPLC is for 
the separation of complex peptide mixtures from digested cell lysates40.  
Size exclusion LC (SEC) also known as gel permeation or gel filtration chromatography 
separates analytes based on size41. This is useful for the determination of tertiary or quaternary 
structures of proteins or protein complexes41. In addition, molecular weights can sometimes be 
determined as well41.  
Ion exchange LC (IEX) has two variants, anion and cation exchange, and both separate 
analytes based on attraction to charged sites on the stationary phase42. Ions of the same charge as 
the stationary phase are eluted with little or no interaction whereas oppositely charged ions are 
retained based on their ionic strength42. The mobile phase is composed mainly of increasing 
concentrations of counter-ions (sodium chloride) that competes with the binding of analytes42. 
Furthermore, pH can be varied in the mobile phase such that the charge of the analyte of interest 
is changed which subsequently affects its binding to the stationary phase42. Typical applications 
of IEX are water purification and protein purification42,43.  
Bio-affinity chromatography separates based on the specific interaction of proteins with 
their respective ligands44. These ligands are covalently linked to the packed beads in the 
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stationary phase. Elution can be performed in two ways: biospecific elution which involves 
competing ligand in the mobile phase and aspecific elution which involves changes in pH and 
salt concentrations that can weaken the interaction of the protein with the affinity column44. As 
the name implies, this method is specific to certain analytes and the resulting products are highly 
pure.  
For detection, typically UV spectroscopy is used where the wavelength is set to a value at 
which the analytes can absorb35. However, LC combined with MS as a detection system is much 
better because of higher sensitivity and the added selectivity feature provided by MS45. LC-MS 
has many applications, however, it is most renowned in the “omics” fields such as proteomics, 
metabolomics, lipidomics, and glycoproteomics45–49.   
 
1.4 Hydrogen Deuterium Exchange (HDX) 
 HDX is a chemical reaction whereby labile hydrogen atoms undergo exchange with 
deuterium. It serves as a powerful analytical technique to probe protein conformation and 
dynamics by monitoring the isotopic exchange of protein backbone amides50. HDX was first 
observed by Kaj Ulrik Linderstrøm-Lang using ultracentrifugation and Englander et al. further 
explored and measured HDX to single amide resolution using nuclear magnetic resonance 
(NMR)51. Despite its high resolving powers, NMR has its limitations such as difficulties in 
studying transient species, long acquisition times due to complex pulse sequences ultimately 
resulting in data that represents protein in an equilibrium ensemble, and requirement for highly 
concentrated samples. Nevertheless, HDX NMR is still widely used in studies of protein-ligand 
binding and protein folding/unfolding. HDX was first implemented on LC-MS by Zhongqi 
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Zhang and David L. Smith  in 1993 and provided the foundation for the majority of HDX MS 
workflows still widely used today52. Figure 1.7 shows the conventional “bottom-up” HDX 
workflow using cytochrome c. Briefly, the protein was reacted in excess deuterium solution. The 
reaction was quenched and the labelled protein was subsequently digested using pepsin in cooled 
acidic conditions (pH 2.5, 0°C). The labelled peptides were further separated by LC and detected 
by mass spectrometer52–54. HDX MS, unlike HDX NMR, has no limitations on protein size and is 
highly sensitive requiring protein concentrations down to the nM range.   
 
Figure 1.7. Conventional “bottom-up” HDX workflow. HDX is initiated when the protein 
(cytocrhrome c) is allowed to mix with deuterated buffer for a set time. During this mixing time, 
solvent exposed amides will exchange much faster than protected regions. Subsequently, the 
reaction is quenched holding the label in place and digested in acidic conditions. Peptides are 
then separated and resolved using LC-MS yielding spatial resolution HDX data which are then 
mapped onto 3-D protein structures. Global HDX experiments work in a similar fashion, 
however without the quenching and digesting steps.  
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 1.4.1 HDX- Fundamentals 
 Labile hydrogen atoms bound to sulfur, oxygen, and nitrogen undergo rapid isotopic 
exchange due to the electronegative heteroatoms55. Exchange of backbone amide hydrogens, 
however, is highly dependent on pH and temperature and can be quenched under the right 
conditions (pH 2.5, 0°C). Hence HDX rates of backbone amide hydrogens serve as a sensitive 
probe for protein conformation. The HDX reaction can be acid (H3O
+), base (OH-), and water 
(H2O) catalyzed, however, effects from water catalysis are minimal.  The chemical HDX rate 
constant (Kch) of an amide in an unstructured peptide is as follows: 
Kch=kint,H[H
+]+kint,OH[OH
-]+kint,H2O[H2O]                                       (4) 
where kint,H, kint,OH, and kint,H2O are the intrinsic rate constants for the acid, base, and water 
catalyzed reactions respectively56,57. Figure 1.8 demonstrates the mechanisms of base- and acid- 
catalyzed backbone amide HDX. In base-catalysis, OH- abstracts the amide proton through a 
nucleophilic attack forming an amidate ion. Subsequently, the amidate ion is then reprotonated 
by the deuterium atom from deuterated water (deuterium oxide, D2O). Acid catalysis involves 
two possible mechanisms: N-protonation or O-protonation. N-protonation is similar to that of 
base catalysis except the protonation order is reversed; the initial step is the protonation of the 
backbone amide hydrogen by D3O
+ followed by deprotonation of the N-protonated intermediate. 
O-protonation involves protonation of amide oxygen by D3O
+ leading to amide proton 
acidification. The amide proton is then abstracted by water producing imidic acid which is 
subsequently protonated by D3O
+ to form the labeled amide58. 
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Figure 1.8. Chemistry of base- (A) and acid- (B and C) catalyzed backbone amide HDX 
mechanisms. Under native conditions (pH 7.0), HDX is mainly driven by base catalysis where 
the backbone amide is deprotonated by deuterium hydroxide. Acid catalysis can occur via N-
protonation (B) and O-protonation (C). N-protonation mechanism is similar to base catalyzed 
HDX except the protonation order is reversed; protonation of amide backbone is followed by 
deprotonation. O-protonation occurs through acidification of the amide backbone upon amide 
oxygen protonation resulting in the formation of imidic acid. This imidic acid is then deuterated 
to form the deuterated amide backbone. Amides adjacent to electron withdrawing and donating 
sidechains proceed through O- and N-protonation respectively58. Adapted and modified from 
Weis59. 
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 As mentioned previously, HDX rates are highly dependent on pH and temperature. For 
example, the rate constants determined for a poly-DL-alanine peptide at 20°C has kint,H = 41.67 
M-1min-1, kint,OH = 1.12 x 10
10 M-1min-1, and kint,H2O = 3.16 x 10
-2 M-1min-1. From these data, it is 
apparent that base catalyzed rates far exceed the other two with water catalysis being 
negligible56. A plot of log(Kch) vs pH generates a V-shaped chevron curve with a characteristic 
minimum (pHmin) at pH 2.5-3.0 at which the acid and base catalyzed HDX are equal
57. Typically, 
HDX is performed at pH 7 which is relevant for most proteins and quenched at pH 2.5. This 
decrease in pH decreases the HDX rate by approximately 4 orders of magnitude56,57. Hence by 
reducing pH, the reaction can be quenched sufficiently such that MS can detect differential 
changes in deuterium incorporation. 
 An increase in temperature increases the chemical HDX exchange rates by altering the 
water ionization constant, kw (increases the concentration of OH
-). The relationship between Kch 
and temperature can be explained using the Arrhenius equation, 
Kch (T)=krc(293)exp(
−𝐸𝑎 
𝑅
(
1
𝑇
−
1
293
))                                     (4) 
where krc(293) is the reference constant, Ea is the activation energy for acid (14 kcal mol
-1), base 
(17 kcal mol-1), and water (19 kcal mol-1) catalyzed exchange, and R is the gas constant (8.134 J 
mol-1 K-1). This relationship is an exponential function56. Decreasing temperature from 25 to 
0°C, leads to approximately a 14-fold decrease in exchange rate. Hence, finely controlling these 
two factors, pH and temperature, can greatly reduce the exchange rate as well as the back-
exchange reactions52,56.  
 In addition to pH and temperature, sequence can also have an effect on Kch, especially 
inductive or steric effects from neighbouring side chains56. Although the effect is not as 
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pronounced as the previous two factors, they should be considered in some cases. For example, 
polar side chains increase the acidity of the amide backbone through inductive effects hence 
accelerating the exchange rates. Bulky side chains, however, decreases the rate by steric effects 
and could result in a 10-20 times slower exchange rate based on pH56.  
 
1.4.2 HDX- Well Folded Proteins 
 Most proteins in nature exhibit well-defined tertiary folding with the exception of 
intrinsically disordered proteins (IDPs). In the case of higher order structured proteins, the major 
factors affecting HDX rates mainly arise from intramolecular hydrogen bonding and solvent 
accessibility rather than the effects of pH and temperature60,61. HDX rates of amides in 
unstructured peptides can have a half-life of milliseconds to seconds, whereas in native folded 
proteins, they can range from milliseconds to years60! Furthermore, proteins in solution are not 
static, but exhibit transient conformational dynamics (breathing motions)50,62. During this brief 
period, some intermolecular H-bonds are broken, making them readily available for HDX. Hence 
the HDX kinetics for various states of proteins can be expressed by: 
cl (H)
kop
⇄
kcl
 op (H)
k𝑐ℎ
→
D2O
op (D)
kcl
⇄
kop
cl  (D)                              (5) 
where cl and op corresponds to closed and open states respectively. H and D represents 
protonated and deuterated states. kop and kcl are the rate constants for the opening and closing 
states. Proteins in solution are in equilibrium between both states hence the exchange process is 
mainly affected by the rates of unfolding/folding and its intrinsic exchange rate, kch. Hence the 
exchange rate constant (kHDX) of protected amides can be expressed as
62,63: 
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𝑘𝐻𝐷𝑋 =
𝑘𝑜𝑝 𝑋 𝑘𝑐ℎ
𝑘𝑜𝑝+𝑘𝑐𝑙+𝑘𝑐ℎ
                                               (6) 
Under native conditions, the frequency of folding far exceeds unfolding (kcl>>kop), so equation 
(6) could be reduced to: 
𝑘𝐻𝐷𝑋 =
𝑘𝑜𝑝 𝑋 𝑘𝑐ℎ
𝑘𝑐𝑙+𝑘𝑐ℎ
                                                  (7) 
Based on the timescale of the opening and closing events, there are two possible scenarios: 
kcl>>kch, and kcl<<kch. When kcl<<kch, the rate of chemical exchange is much faster compared to 
the rate of protein folding. Hence, during the unfolding event, the solvent exposed amide 
backbones are all exchanged due to sufficient time for the exchange process to occur. In this 
scenario, the amide exchange rate, kHDX, is highly dependent on the rate of protein unfolding, kop. 
This mechanism is called EX1 kinetics and equation (7) can be further simplified to: 
𝑘𝐻𝐷𝑋 = 𝑘𝑜𝑝  (𝑘𝑐𝑙 ≪ 𝑘𝑐ℎ,   𝐸𝑋1)                                         (8) 
Most stable proteins at their physiological conditions, however, exhibit a much faster refolding 
rate compared to chemical exchange rate, kch , in other words, kcl>>kch. This is called EX2 
kinetics where exchange occurs through multiple opening and closing states of the protein. 
Hence, EX2 probes the structural fluctuations occurring in the native state. Equation (7) can be 
reduced to: 
𝑘𝐻𝐷𝑋 =
𝑘𝑜𝑝 𝑋 𝑘𝑐ℎ
𝑘𝑐𝑙
= 𝐾𝑜𝑝 𝑋 𝑘𝑐ℎ (𝑘𝑐𝑙 ≫ 𝑘𝑐ℎ, 𝐸𝑋2)                              (9) 
where Kop defined by the ratio of kop/kcl is the equilibrium constant of the opening and closing 
reaction.  
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Equation (9) demonstrates that kHDX is proportional to Kop and this information can be used to 
determine thermodynamic properties of protein as shown in equation (10).  
∆𝐺° =  −𝑅𝑇𝑙𝑛𝐾𝑜𝑝 = −𝑅𝑇𝑙𝑛(𝑘𝑜𝑝 𝑘𝑐𝑙)⁄ =  −𝑅𝑇𝑙𝑛(𝑘𝐻𝐷𝑋 𝑘𝑐ℎ)⁄ =  𝑅𝑇𝑙𝑛(𝑃𝐹) (10) 
where R is the ideal gas constant, T is the temperature, and PF is the protection factor. A PF=1 
represents no protection from exchange such as in the case of unstructured peptides. When PF>1, 
there is some level of protection from exchange due to the surrounding environment (i.e., solvent 
protection or the presence of secondary structure)64,65. 
Another advantage of using MS over NMR is its ability to detect EX1 versus EX2 
kinetics (resulting spectrum from NMR is an average). For example, Figure 1.9 demonstrates the 
isotopic envelope evolution as a result of either EX1 or EX2 exchange. EX2 kinetics exhibits 
characteristic binomial isotopic distribution where its centroid value increases gradually as a 
function of mixing time. In contrast, regions undergoing EX1 kinetics exhibit bimodal isotopic 
distribution patterns because of full deuteration during a single opening event. This pattern could 
be completely separated or partly merged depending on kop
66
. 
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Figure 1.9. MS characteristics of EX1 and EX2 kinetics. EX2 kinetics exhibit a characteristic 
binomial distribution of isotopic envelope and increases gradually as a function of mixing time. 
EX1 kinetics is characterized by distinct envelopes and the intensities vary as a function of 
mixing time. Adapted from Weis59. 
 
1.4.3 HDX- Disordered Proteins 
Intrinsically disordered proteins (IDPs) explore conformational spaces where most of the 
amide hydrogens are exposed which translates to IDPs transiently occupying its closed state, 
kop>kcl
59,67. The approximation above for folded proteins assumes that the rate of unfolding is 
much smaller than rate of folding, kcl+kch>>kop
68. However, if the interconversion between open 
and closed states are much faster than the chemical exchange rate as in the case of IDPs 
(kch<kcl<kop), then the EX1 and 2 regime would never occur (refer to equation (6) and (7)), 
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contradicting the approximation59. To explain the HDX data for IDPs, the Linderstrøm-Lang 
mechanism must be modified without any approximations and as follows 59,69. 
[𝑐𝑙] = (1 − 𝑓𝑜𝑝)[(
 𝑘α
𝑘α− 𝑘β
)e-kβt -(
 𝑘β
𝑘α− 𝑘β
) e-kαt]                                  (11) 
[𝑜𝑝] = 𝑓𝑜𝑝[(
 𝑘α−𝑘𝑐ℎ
𝑘α− 𝑘β
)e-kβt -(
 𝑘β−𝑘𝑐ℎ
𝑘α− 𝑘β
) e-kαt]                                      (12) 
[𝑒𝑥] = 1 − [(
 𝑘α−𝑘𝑐ℎ𝑓𝑜𝑝 
𝑘α− 𝑘β
)e-kβt -(
 𝑘𝑐ℎ𝑓𝑜𝑝 −𝑘β
𝑘α− 𝑘β
) e-kαt]                                (13) 
In equations (11-13), [cl], [op], and [ex] represents the concentrations of closed, open, and 
exchanged forms respectively. kα and kβ represent fast and slow processes respectively. The 
kinetics in equations (11-13) demonstrate biexponential functions and under steady state 
conditions when kcl+kch>>kop, the chemical exchange rate from equation (13) could be reduced 
to:  
[𝑒𝑥] = 1 −e^-(
𝑘𝑜𝑝 𝑘𝑐ℎ
𝑘𝑐𝑙+𝑘𝑜𝑝+𝑘𝑐ℎ
)t                                                (14) 
This can be further reduced to explain EX1 and EX2 kinetic regimes using equations (8) and 
(9)59,69. Despite the complexity of the equations, one can still derive insights from HDX of IDPs. 
For example, bottom-up HDX (peptide-level) generates HDX kinetics that are segment-
averaged, which are summations of a series of equations. With enough overlapping peptides, one 
can potentially deduce exchange rates of individual sites59. There have been several studies 
where variants of the above equations were used to study IDPs65,65,70–72. For example, Keppel et 
al. used PF to map the disordered to ordered transition upon coupled binding of CREB binding 
protein and activator of thyroid and retinoid acid receptors65.  
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Residual secondary structures can also be studied using HDX56,73. For example, the 
kinetics will exhibit the same level of deuterium uptake however at an attenuated rate due to 
formation of transient structures56,73. Similarly, when the population of transient structures are 
~6% and the interconversion dynamics are slow (1s in closed state), the kinetic rates are 
comparable with attenuated deuterium uptake56,73. These examples illustrate that even small 
perturbations of order in IDPs can be detected via HDX. These states, however, are invisible in 
other spectroscopic techniques74.  
 
1.4.4 Time Resolved HDX (TR-HDX) 
Conventional HDX workflows employ labelling times as short as 10s and is well-suited 
for characterizing changes in structure and conformational dynamics of proteins75. However, 
regions of proteins involved in biological activities are often flexible or unstructured and 
undergo full deuterium exchange under conventional mixing times65,76,77. Hence to probe these 
weakly structured regions, millisecond timescale HDX should be employed.  
The first millisecond HDX measurements were conducted using quench-flow pulse 
labeling and analysed by NMR78,79.  Dharmasiri and Smith then introduced millisecond HDX 
labelling using quenched-flow MS for spatially and time resolved measurements80.  Konermann 
and coworkers pioneered continuous-flow millisecond HDX, however the technique at the time 
lacked spatial resolution81. Ultimately, Wilson and coworkers achieved spatial resolution using a 
‘bottom-up’ workflow through the use of a microfluidic device (Figure 1.10)72. Briefly, the setup 
consists of a kinetic mixer for millisecond to second HDX labeling, a static mixer such as a 
Valco-T mixer for HDX quenching, a microreactor containing acid proteases such as pepsin 
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and/or protease XIII crosslinked to agarose beads for rapid digestion, and an on-chip 
incorporated electrospray needle72,82. The entire process is performed online with labelling times 
ranging from 40ms to 12s. Labelled proteins are efficiently digested in the proteolytic chamber 
in under 8s minimizing back-exchange in the absence of cooling. Furthermore, the electrospray 
needle incorporated at the outlet of the microfluidic chip enables online analysis72.  
 
 
Figure 1.10. A schematic depiction of TR-HDX performed on a microfluidic device. The 
kinetic mixer and acid channel (pH 2.4) are connected to a Valco T-mixer. HDX occurs in the 
kinetic mixer and is efficiently quenched in the conjunction of the Valco T-mixer. Labelled 
protein is then transferred to the downstream proteolytic chamber containing either pepsin or 
protease XIII covalently linked to agarose beads where digestion occurs. The distal capillary is 
used as an ESI source to transfer the digested peptides into the mass spectrometer. 
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TR-HDX with millisecond mixing times can probe the relative conformational flexibility 
such as changes in dynamics upon ligand or protein binding. An example of early work on the 
study of weakly ordered regions was on mildly denatured myoglobin81. Using subsecond mixing 
times (7ms to 3.1s), Simmons et al. were able to detect five similar folded states, one EX1, and 
three EX2 transition states providing a detailed picture of conformational ensembles during the 
millisecond mixing regime81. Another example of TR-HDX on weakly structured regions was 
performed on native cytochrome c72. The authors implemented TR-HDX on a microfluidic 
platform with the bottom-up HDX approach. The results were reported in terms of segment-
averaged PFs ranging from 10-36. The unstructured regions that exhibited the highest PFs were 
those in close contact with the heme cofactor.  
TR-HDX has been used to study transient intermediate species during the protein folding 
events that is invisible by other classical techniques. For example, when ubiquitin was allowed to 
fold for 40ms, TR-HDX identified a species that acquired a folded-like ESI charge state 
distribution, yet exhibited a denatured HDX profile83. Although these are not structurally 
resolved, with application of bottom-up TR-HDX workflow, several intermediates have been 
well resolved for myoglobin, cytochrome c, calcium binding to S100A11 signalling protein, and 
bacteriorhodopsin84–86.  
TR-HDX has also been implemented to isolate and characterise catalytically active 
intermediates. For example, a study conducted by Liuni et al. showed that resting and acyl-
enzyme states of chymotrypsin sampled the same conformational space. Interestingly, however, 
their rates were different; the acyl-enzyme species was undergoing faster conformational 
searching during catalysis which the authors described as “intensified dynamics”87. This was a 
novel finding and a new enzyme catalysis model proposed through use of TR-HDX, highlighting 
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the potential of this technique in providing insights to new fundamental mechanisms in enzyme 
catalysis. 
 
1.4.4.1 TR-HDX- Application: IDDs and IDPs 
IDPs lack or have very little secondary or tertiary structures67. Under physiological 
conditions, IDPs sample a wide range of conformational ensembles67,88. Despite its unstructured 
nature, there are small regions that adopt transient secondary structures that are invisible to the 
conventional HDX workflow89. However, TR-HDX can detect these fleeting species due to the 
fast labelling timescale.  
Recently, TR-HDX was applied to study a conformational ensemble shift in the IDP tau 
upon hyperphosphorylation70. Please refer to Chapter 3 for the study and detailed explanation. 
Briefly, the study implemented TR-HDX on a microfluidic device to probe the PFs of native and 
hyperphosphorylated tau. Tau hyperphosphorylation represents one of the hallmarks in 
Alzheimer’s disease (AD)90. In the native state, substantial protection was observed in the 
aggregation prone regions called hexapeptides that are buried in the core of the protein. 
Furthermore, the regions surrounding the hexapeptides also showed attenuation in deuterium 
uptake, indicative of a protection mechanism. Upon hyperphosphorylation, however, one of the 
hexapeptides was solvent exposed along with release of the native globular conformation. 
Exposure of this hexapeptide could potentially provide an aggregation template for the seeding 
process. This study provided a detailed picture of the conformational shift that occurs upon 
hyperphorylation as well as evidence for the causative role of tau amyloidosis in AD70.  
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In the same year, Keppel and Weis applied millisecond HDX and reported the presence 
of residual helical structure in the C-terminus of activator of thyroid and retinoid acid receptor 
(ACTR)91. Their analysis approach was different in a sense that instead of fitting HDX kinetic 
data, they interpolated half-life exchange (time needed to reach 50% deuterium uptake) to 
quantify the data91. The N-terminus of ACTR exhibited faster exchange compared to the C-
terminus. The attenuation in C-terminus was rationalized by the presence of aspartic acid which 
slows the exchange rate via electrostatic repulsion56. Nevertheless, other complimentary 
techniques such as NMR and computational simulation supported the presence of transient 
helical structure in the C-terminus91,92.  
 
1.5 IDPs- Current Perspective 
Proteins are powerful molecular machines that are constantly at work to keep all of us 
viable93. This reason alone spurred structural biologists to gain insights into their chemistry and 
biological functions. It has been well established that proteins require motions/dynamics to carry 
out their functions and these motions sample a wide range of conformational space at different 
timescales with varying amplitudes giving rise to different conformational states93,94. Ultimately, 
the goal is to characterise proteins’ free energy landscape with all relevant conformational states 
that are catalytically active and their respective kinetics and thermodynamics94. Thus far, there is 
overwhelming data on proteins’ structures in their ground states because these are the most stable 
species in solution and also due to technical limitations of the technologies present at the time. 
This scope has provided a strong correlation between their well folded three-dimensional 
structure and their function resulting in the concept of the structure-function paradigm95. 
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However, with the advent of high resolution biophysical techniques such as NMR, it is becoming 
increasingly evident that higher energy states are more relevant to protein function rather than 
their ground states. This often challenges the structure-function paradigm and lock-and-key 
mechanisms suggesting that protein function is dictated by their dynamics rather than their 
structure96,97. Proteins at higher energy states contain more “disordered” regions and are highly 
dynamic exhibiting large degrees of motion, interconverting between different heterogeneous 
conformers93.  
The lack of structure in IDPs and IDDs can have several advantages over folded proteins. 
For example, IDPs can provide a larger surface area for interactions with various binding 
partners hence exhibiting their versatility98,99. Furthermore, their malleability enables them to 
finely tune affinities towards various partners with different degrees of specificity and also 
present motifs that are more accessible for post-translational modifications (PTMs)94,100,101. For 
example, IDPs sometimes exhibit disorder-to-order transition upon binding with high specificity 
and low affinity88,93. These modes of binding are essential in regulatory and signalling processes 
which involve transient protein-protein interactions102,103. Interestingly, disordered regions 
comparatively have higher mutation rates without affecting stability or function93,104. 
Furthermore, disorder may help limit overall protein size and crowding effects in cells105. 
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1.5.1 IDP- Structure and Function 
IDPs and IDDs are disordered mainly due to their primary sequences which are 
predominantly comprised of charged polar residues as well as glycine and proline with minimal 
hydrophobic residues106. Functionally, IDPs are very diverse due to the presence of multiple 
binding motifs, encompassing essential biological roles (i.e., transcription, signalling, cell cycle 
regulation) to pathological roles (amyloidosis resulting from protein aggregation)94,102,103. 
Energetically, IDPs lie high on the free energy landscape and sample numerous conformations 
that can be functionally relevant, enabling recognition of different binding partners to carry out 
essential biological functions (Figure 1.11)94,107. However, when misregulated either through 
faulty PTMs or a degradation pathway, IDPs can funnel through an “off-pathway” resulting in 
misfolded toxic oligomers107. These toxic intermediates are problematic because typically 
hydrophobic residues are solvent exposed, presenting a sticky surface allowing for other 
monomeric forms to undergo aggregation through intermolecular interactions. 
 Most of the time, IDPs mediate protein recognition through numerous binding motifs 
and the resulting complexes facilitate allosteric regulation108,109. Furthermore, due to 
accessibility, IDPs and IDDs are often a target for PTMs that act as molecular switches and also 
affect their binding affinities towards certain targets93. It is also well known that many IDPs 
interact with their partners in an extended conformation such that it wraps around their targets, 
increasing the buried surface area resulting in high specificity98,99. In addition, IDPs act as 
scaffolding or “hub” proteins through distinct motifs to integrate and localise signals that are 
central to protein interaction networks101,110,111. Due to their high charged residue content, IDPs 
are highly soluble and can act as a “detergent” to facilitate solubility of other proteins as well94. 
For example, the disordered region of clusterin (glycoprotein) can solubilise 
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bacteriorhodopsin112. However, when hydrophobic residues are exposed to the solvent, there is a 
tendency for them to aggregate with other monomers resulting in aggregation based diseases 
such as AD70,90,94,113. Furthermore, if their concentrations are too high, they can bind to other 
physiological targets. Examples include studies of SH2 and PDZ domain containing 
proteins114,115. Hence, the tight regulation of IDPs is essential to maintain cell viability. This is 
done through help of scaffolding proteins and through degradation pathways (IDPs and IDDs are 
susceptible due to their unstructured nature)93,116. Despite the tight regulation, there are 
exclusions where IDPs need to be present in high concentrations or for long durations because 
they become part of a stable protein complex to perform relevant biological functions117. An 
example is the activation of tumor suppressor protein, p53, in response of stress stimuli. In 
unstressed cells, p53 is bound to its negative regulator mdm2 and is targeted for degradation. 
However, upon stress, its N-terminus is phosphorylated which results in subsequent p53 
activation118.  
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Figure 1.11. Schematic of the protein folding and aggregation landscape of IDPs. The funnel 
is split into two sides; physiological (light green) and toxic (dark green). Left side represents 
newly synthesized unfolded protein funneling to its native state through a multitude of 
intermediate conformations via intramolecular interactions and help of chaperone proteins. Right 
side represents folding of conformations into toxic oligomers, aggregates, and amyloids through 
intermolecular interaction when misregulated. Adapted and modified from Turoverov et al119. 
 
1.5.2 IDP association with human diseases 
 Although IDPs and IDDs are deeply involved in crucial biological functions, their 
dysfunction can result in a wide range of human diseases120. For example, IDP dysfunction and 
aggregation is the main culprit in numerous neurodegenerative diseases such as AD and 
Parkinson’s. Furthermore, it was found that ~79% of cancer-associated proteins contain 
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intrinsically disordered regions of at least 30 residues121. In the case of human papillomavirus 
(HPV) , it was shown that an increased amount of non-structural proteins (E6 and E7) resulted in 
a high risk class of HPVs122. So why are IDPs prone to development of pathological diseases? 
Despite IDPs versatility and advantages, a subset of those features are also the key drivers in the 
disease pathology120. For example, the larger surface area of IDPs and IDDs for PTMs make it 
more susceptible for impaired modifications resulting in abolishment in some of the essential cell 
signaling processes as in the case of  p53 N-terminal transactivation domain (NTD)120. 
Alternative splicing (AS) can diversifies the proteome and higher frequency of AS could be 
tolerated in IDPs because its functional and structural features are not perturbed123,124. However, 
this also makes IDPs more vulnerable such that it could weaken or abolish essential protein-
protein interactions as well as generating fragments that are more prone to forming protein 
aggregates43,120,124. Abnormal AS is associated with myotonic dystrophy, cancer, and AD, just to 
name a few43,90,125,126.  
The most notable pathological phenomenon for IDPs and IDDs, however, is the 
formation of protein aggregates due to protein misfolding or “off-pathway folding” as in the case 
of numerous neurodegenerative diseases and amyloidosis116,120. Misfolding can occur due to 
impaired regulation, missignaling, and misidentification120. One of the common features 
resulting from misfolding is the aggregation or the formation of highly-ordered and stable 
filamentous protein aggregates known as amyloid fibrils127. The fibrils are comprised of cross β-
sheets in the core running perpendicular along the fibril axis127. Two to six protofilaments are 
associated laterally or twisted forming larger fibrils 4-13nm in diameter127. Structurally, 
amyloids from different diseases are similar in morphology. However, the aggregation-prone 
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intermediates are vastly different for different IDPs and it is speculated that these are the toxic 
species in the formation of the diseases120.  
 
1.5.3 IDP- p53 N-terminal Transactivation Domain and Cancer 
p53 is a tumor suppressor protein that plays a major role in cellular stress responses such 
as DNA damage, hypoxia, and other stresses128. It is known that its inactivation either through 
mutation or deregulation of associated pathways can result in the majority of known cancers129. 
Once activated, it regulates the cellular response of apoptosis, cell cycle arrest, and DNA repair 
depending on the nature of the stress128 (Figure 1.12). Structurally, p53 is composed of mainly 
four distinct domains: NTD, DNA binding domain, tetramerisation domain, and C-terminal 
domain128. p53 becomes activated and stabilised through a series of PTMs128,130,131. Most 
common is phosphorylation of the p53 NTD that is critical for protein-protein interactions in the 
regulation of its activity and stability128. Furthermore, it also plays a major role in dictating 
modifications of other domains of the protein such as acetylation of the C-terminal domain130. 
The NTD is intrinsically disordered and can provide multiple conformational states facilitating in 
interaction of numerous binding proteins through the modulation of PTMs. The NTD can be 
divided into two subdomains: TAD1 and TAD2. Both of these domains are known to contain 
transient secondary structures in the unbound state, however it has been shown to adopt helical 
structure upon complex formation with binding partners through coupled folding driven by 
hydrophobic interactions132–134. p53 NTD has been shown to interact with various transcriptional 
regulatory proteins such as TATA binding protein, CBP/p300, and p62 subunit of general 
transcription factor II H (GTFIIH)134–136. Most of these interactions are dictated through PTMs 
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such as phosphorylation because it modulates the binding affinities of different binding partners 
that are known to bind at the same sites129. For example, double phosphorylation at Ser46 and 
Thr55 increases its binding affinity to Tfb1 in an additive manner129,134.  
Hence p53 NTD plays an important role in p53 activation and downstream activities. 
Furthermore, phosphorylation can serve as a molecular on/off switch. Studies from mouse 
models further highlighted the importance of NTD and its modifications. Mutant knock-in and 
knock-out studies demonstrated impairment in p53-dependent apoptosis and/or G1/S cycle 
arrest. For example, homozygous mice containing Ser23Ala mutation, Ser23 (human S20) is an 
important phosphorylation site for p53 activation, had much shorter life spans and developed B-
cell lymphoma137. Many of these mutations on the NTD reduced p53 activity by abolishing p53 
interactions with other transcriptional coactivators.  
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Figure 1.12. Simplified mechanism of p53 activation. p53 is shown in blue oval nodes, N and 
C represents the N- and C-termini whereas the middle node is the DNA binding and 
tetramerisation domain. When unstressed, p53 is bound to its negative regulator, mdm2 and is 
targeted for degradation. Upon cellular stress such as radiation induced DNA damage, p53 is 
activated by phosphorylation at its N-terminus by kinases such as chk1 and 2. This results in 
dissociation of mdm2 and stabilization of p53. Once activated, p53 induces downstream 
pathways involved in cell cycle arrest, apoptosis, and DNA repair.  
 
1.5.4 IDP- Tau and Alzheimer’s Disease 
Tau is an IDP that has a function in microtubule binding (Figure 1.13)90. Under 
physiological conditions, tau mainly functions in binding and stabilizing microtubules, 
maintaining the cytoskeleton morphology of the neuronal cells90,138. There are total of 6 tau 
isoforms generated by alternative splicing in humans that range from 352-441 amino acids139. 
These are also intrinsically disordered with minimal secondary structures138,139. Structurally 
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htau40, full length tau, is composed of projection N-terminus domain and assembly C-terminus 
domain90,138. The projection domain may play a role in establishing a “clear zone” that is 
responsible for adhering to other tau monomers or other microtubule binding proteins140. The C-
terminal domain contains 4 repeats of the same 31-32 amino acid sequences that are important 
for microtubule binding as well as formation of neurofibrillary tangles (NFTs) in AD90,138. 
Despite the disordered nature of tau, it still adopts a fold that resembles a paperclip where both 
N- and C- terminals are in contact with the repeat domain regions141. Tau consists mainly of 
hydrophilic and charged residues; an acidic stretch is near the N-terminus followed by the basic 
domains90. Another important feature of tau is the presence of proline rich regions in between the 
N and C-termini. This region mostly contains Ser-Pro (SP-) or Thr-Pro (TP-) motifs that are 
readily phosphorylated in AD90,142.  
Tau sparked major interest when its aggregation was discovered in AD and other 
taupathies90. Mutations in tau have been shown to be the cause of other neurodegenerative 
diseases such as frontotemporal dementia, Parkinson’s disease, and progressive supranuclear 
palsy143,144. Now it is becoming more evident through animal models that tau is the bullet in AD 
pathogenesis whereas Aβ is the trigger145. Interestingly, tau alone when misregulated is still able 
to manifest as a risk factor. For example, in vivo studies showed that mice with one or both tau 
genes knocked out but still overexpressing Aβ did not show any memory impairment. 
Furthermore, its plaque load as a result of Aβ aggregates were the same as that of a parental 
strain containing both tau genes.  However, when both were overexpressed, the mice manifested 
severe memory impairment and learning deficits146.  
Tau phosphorylation is required for careful regulation of microtubule binding147. 
However, hyperphosphorylation can have detrimental effects and represents one of the hallmarks 
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of AD as aforementioned. In AD patients, the level of phosphate incorporation is at least four 
times higher than healthy brains148. Tau is an easy target for phosphorylation by multiple kinases 
and contains at least 45 phosphorylation sites149. Most of these sites are targeted by proline-
directed kinases (e.g. Glycogen Synthase Kinase-3β (GSK3β), Mitogen-Activated Protein 
Kinase (MAPK), cyclin-dependent kinase 2 (cdc2), c-Jun N-terminal Kinase (JNK), and cyclin 
dependent kinase 5 (cdk5)) due to the presence of many SP- or TP-motifs within the tau 
sequence. However, other non-proline directed kinases such as AMPK related families can also 
phosphorylate tau90,150. Hence tau phosphorylation can be used as a biomarker for AD and thus 
far few antibodies have been raised against these phosphosites, some examples include PHF1 
that recognizes pS396 and 404, AT8 for pS202 and 205, and AT100 for pT212 and S214151,152. 
Upon hyperphosphorylation, tau loses its affinity for microtubules, and has higher 
affinity to itself90,142. This subsequently results in tau self-assembly and aggregation into paired 
helical filaments (PHF) or NFTs90. PHFs are amyloids and are characterized by well-ordered 
stacked β-sheet rich structures153. The propensity for such formation is encoded in repeat regions 
2 and 3 containing short hydrophobic residues called hexapeptide motifs154. The core of the PHF 
(~20 residues of repeat regions 2 and 3) is established through axially stacked cross-β structures, 
however, the remainder of the protein (N-terminus and the rest of the C-terminus) is still highly 
mobile even in the aggregated state and has been described as a “fuzzy coat”155,156.  
Other modifications such as tau proteolytic cleavage, oxidation, glycosylation and 
acetylation can also play a role in AD90. Cleavage of N- or C- termini by caspases has shown to 
abrogate the paperclip fold and enhance the aggregation process157. Oxidation of the cysteine 
residues can crosslink to form disulfide bonds with other tau monomers, enabling a faster 
aggregation process90. N-glycosylation can aide in the hyperphosphorylation process158. Lys280 
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acetylation impairs tau binding to microtubules, inhibits tau degradation and also hastens tau 
aggregation159. 
 
Figure 1.13. Tau: physiological function and mechanism underlying AD. Under 
physiological conditions, tau binds to microtubules stabilizing the cytoskeleton of neuronal cells. 
In AD, however, tau is hyperphosphorylated resulting in its dissociating from microtubules and 
initiating self-aggregation ultimately forming NFTs. Adapted and modified from Citron160. 
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1.6 Research Objectives 
IDPs and IDDs pose challenges to conventional biophysical techniques due to their 
intrinsic dynamic nature. TR-HDX, however, represents an alternative powerful structural 
labeling technique that can probe the dynamic and structural ensembles of these proteins and 
domains. Chapters 2-4 will implement a TR-HDX microfluidic chip to conduct structural studies 
on IDPs at sub-second timescales. Chapter 5 will implement gas-phase HDX coupled to DMS 
technology to study solution phase protein structures. 
Chapter 2 focuses on the effect of phosphorylation on the structural ensemble of p53 
NTD and its binding affinity in disordered regions in free form as well as upon binding to PH 
domain of p62 subunit of general transcription factor II H. 
Chapter 3 focuses on elucidating the conformational shift and identification of toxic 
intermediates of tau upon hyperphosphorylation to understand the mechanism driving tau 
pathology in AD and other tauopathies. 
Chapter 4 focuses on the effects of six potential AD drug candidates on the structural 
ensemble of tau protein as well as probing their binding sites. The aim was to study the 
mechanism of aggregate inhibition and to provide structural information to further refine and 
improve the potency of next generation drugs.  
Chapter 5 focuses on applying DMS-HDX to study gas-phase protein conformations of 
folded, partially-unfolded, and unfolded proteins in solution. The aim was to find optimal 
conditions such that unique DMS-HDX profiles were generated for distinct structural features 
that can be applied towards rapid qualitative analysis of structural stability.  
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Chapter 2 
Enhanced Binding Affinity via Destabilization of the 
Unbound State: A Millisecond Hydrogen / Deuterium 
Exchange Study on the Interaction Between p53 and the 
Pleckstrin Homology Domain 
 
A manuscript of this chapter is in preparation. 
 
 Zhu, S.; Khatun, R.; Lento, C.; Sheng, Y.; Wilson, D. J. Enhanced Binding Affinity via 
Destabilization of the Unbound State: A Millisecond Hydrogen / Deuterium Exchange 
Study on the Interaction Between p53 and the Pleckstrin Homology Domain 
 
2.1. Summary 
Presence of intrinsically disordered domains enables a single protein to engage in a 
myriad of binding partners, with PTMs such as phosphorylation modulating target specificity 
and affinity. It is known that phosphorylation can act as a chemical on/off switch for protein 
complexation, however, this is not a satisfying explanation for enhancement of interactions 
through coupled folding that are hydrophobically driven, a common phenomenon of IDPs or 
IDDs through phosphorylation regulated interactions. To determine the effect of phosphorylation 
on the complexation and its binding affinity in disordered regions, we have examined the 
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interaction between p53 NTD and the pleckstrin homology (PH) domain of p62 using TR-HDX. 
Here we demonstrate that phosphorylation did not affect the conformation of bound p53 NTD 
with PH, but instead the modification increased conformational disorder of NTD in the unbound 
state. We propose that this increase in disorder upon phosphorylation creates an elevation in the 
free-energy gap between the free and bound p53 NTD states, resulting in a stronger affinity 
complex. 
 
2.2. Introduction 
It is a widely accepted notion that protein-protein interactions (PPI), whether transient or 
permanent, are critical to many biological processes such as signal transduction, catalysis, and 
cell cycle regulation161–163. Many of these transiently interacting hubs are enriched in disordered 
domains whose function is modulated by PTMs that act as molecular switches130,164. These 
covalent modifications can either alter the local chemistry of the protein itself or their targets, ultimately 
eliciting different effect responses. Although, the structural changes and response effects due to 
PTM have been widely explored, there is increasing evidence that changes in protein dynamics of 
IDDs and IDPs upon PTMs can significantly affect PPI dissociation constants (Kd) without a significant 
change in the native complex ground-state structures165–167. 
p53 NTD is intrinsically disordered and contains many linear motifs that are known to 
interact with various transcriptional regulatory proteins such as TATA binding protein, 
CBP/p300, and p62 subunit of GTFIIH, to name a few134–136. In unstressed cells, the tumor-
suppressor p53 is expressed in low levels and is quite short-lived. However, upon exposure to 
cellular stress conditions, p53 becomes activated and stabilised through a series of 
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PTMs128,130,131. Once activated, it regulates cell cycle responses such as apoptosis, cell cycle 
arrest, and DNA repair depending on the nature of the stress. Phosphorylation of the NTD tightly 
regulates the activity and stability of p53128.  
Interaction of p53 NTD with p62 is important for the recruitment of p53 to the GTFIIH 
complex to initiate the transcriptional elongation process168. Specifically, p53 NTD binds to the 
PH domain of the p62 subunit134. p53 NTD binds to the PH domain with a Kd of 3.2± 0.57 μM in 
its native form, however when phosphorylated at either position Ser46 or Thr55, the Kd increases 
by 6 fold to ~500nM and dual phosphorylation at both sites increases the Kd by ~30 fold to 
100nM134. Binding sites have been identified for p53 NTD/PH domain, with mutagenesis studies 
identifying Lys18 of the PH domain as necessary for the tighter binding observed for 
phosphorylated p53 NTD134. From structural perspective, this tighter interaction is driven by 
stabilization of amphipathic helix of p53 NTD driven by hydrophobic interactions129,134. 
However, this observation alone does not provide a satisfying rationale for phosphorylation 
driven modulation as this helix can be stabilized even in the absence of phosphorylation165,166. 
To examine the effect of phosphorylation-enhanced binding of p53 NTD, the change in 
conformation and dynamics of p53 NTD upon phosphorylation with Chk2 in vitro and binding to 
the PH domain of p62 subunit was conducted using TR-HDX on a microfluidic chip as shown in 
Figure 1.10. As mentioned in the introduction, TR-HDX is a structural labelling technique that 
can detect slightest changes in weak hydrogen bonding network on the millisecond timescale, 
making it amenable to study residual structures in p53 NTD and solvent accessibility upon 
binding to PH59,70,72.  
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2.3 Results and Discussion 
2.3.1 Dynamic analysis of native and phosphorylated p53 NTD 
p53 NTD was phosphorylated in vitro with chk2, a kinase involved in the p53/p62 
interactions, to determine the structural and dynamics changes upon phosphorylation134.  To 
localise the phosphorylation sites, the protein was digested using trypsin or pepsin and 
subsequent enrichment of the phosphopeptides was performed using a titanium dioxide column. 
Identified sites were Ser6, Ser15, Thr18, Ser20, Ser37, and Ser46. MS/MS spectra for the 
phosphorylated peptides are provided in the appendix, Figure A1. Ser15, Thr18, Ser20, and 
Ser37 have been previously identified by Shieh et al. 2000, however the remaining sites (S6 and 
S46) could have been phosphorylated due to a longer incubation time of 120 minutes as opposed 
to 20 minutes169. This was necessary to ensure that phosphorylation goes to completion. 
Phosphorylation at position Thr18 activates p53 by releasing it from its negative regulator, 
mdm2 and phosphorylation of Ser46 enhances binding affinity to PH domain by 6 fold as 
mentioned earlier134,170. Ser46 is phosphorylated by ataxia-telangiectasia mutated (ATM) kinase, 
Dual specificity tyrosine-phosphorylation-regualted kinase 2 (DYRK2), homeodomain 
interacting protein kinase (HIPK), and AMP-activated protein kinase (AMPK). However, this 
site is not known to be substrate for chk2171. 
Next, IMS was performed on both native and phosphorylated p53 to investigate their 
relative cross-sectional areas (CSA) (Figure 2.1). IMS is analogous to electrophoresis where 
separation is based on CSA of gas-phase ions. Based on the chromatogram (Figure 2.1), native 
p53 NTD exhibited two peaks; a major peak corresponding to a drift time of 5.87ms and a minor 
peak at 8.75ms. This illustrates the presence of two gas-phase conformations, with the majority 
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populating a relatively more compact conformation. However, upon phosphorylation, a bimodal 
distribution was exhibited with equal intensities at both 5.87 and 8.75ms. This indicates a shift to 
an overall extended conformation of p53 NTD upon phosphorylation, considering native p53 
NTD is already in a partially collapsed state172. To expand on this finding, TR-HDX was 
performed on both the native and phosphorylated p53 NTD to localize the areas of 
conformational change. 
 
Figure 2.1. Ion mobility chromatograms of native and phosphorylated p53 NTD. 
Comparatively, native p53 exhibited a more compact conformation (solid line) whereas the 
phosphorylated counterpart showed a more extended conformation (dashed line). 
 
For TR-HDX, five mixing time points were acquired in triplicates for both native and 
phosphop53: 0.20s, 0.57s, 0.95s, 1.32s, and 2.06s (Figure 2.2). A sequence coverage of 75% was 
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achieved for both: 8 peptides for native and 16 peptides for phosphop53. This low sequence 
coverage could be due to short residence time in the proteolytic chamber (typically < 8 s) to avoid 
significant back-exchange72,82. Nevertheless, phosphop53 showed a greater deuterium exchange 
globally compared with native. This is in agreement with the IMS data, strongly supporting the 
conclusion that upon phosphorylation, p53 NTD adopts an extended conformation.  
Transient secondary strucutres in p53 NTD has been predicted by computational 
approaches172–174. Furthermore, performing secondary structure propensity using Protein 
Structure Prediction Server showed high helical propensity in residues 16-25, 37-44, and 48-
56172,174. Mapping the HDX data onto a representative 3D ribbon diagram (generated by 
PHYRE2 server using PDB 2GS0 as a template) confirmed the presence of residual secondary 
structures at residues 19-21, 32-43, and 53-59 of native p53 NTD under the fastest mixing time 
regime of 0.20s as shown by lower deuterium uptake (Figure 2.2). However, when the mixing 
time was extended, these transient differences were lost since these are short-lived 
conformations. For example, during 0.57s of mixing, information of the C-terminal end transient 
helix was lost and at 2.06s, all short lived conformations were not detectable.  
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Figure 2.2. HDX data for native and phosphorylated p53 NTD. The data is mapped onto the 
predicted ribbon model by PHYRE2. Deuterium uptake percentage is represented by the color 
scheme shown on the right. 
 
Segment-averaged protection factors can provide the relative thermodynamic stability 
estimation of these residual secondary structures. By dividing a peptide’s intrinsic and observed 
rates, the PF can be calculated. The intrinsic rate is a multiexponential expression that represents 
a unstructured exchange rate for each residue which can be obtained from the online webserver, 
Sphere52,60. Figure 2.3A and B show the segment-averaged PF for unmodified and phosphop53 
NTD respectively (unmodified p53 NTD average PF = 1.89, phosphop53 NTD average PF = 
1.16). Comparatively, phosphorylated p53 NTD showed lower PFs indicating an increased 
conformational dynamics upon phosphorylation. For unmodified p53, the regions predicted to 
have residual structures which are residues 18-21, 32-43, and 53-59 showed greatest PFs (>2). 
These are also the regions that exhibited lowered exchange at the earliest HDX mixing time of 
0.20s  (Figure 2.2). For phosphop53 NTD, however, all the regions exhibited PF below 1.3 
indicating a near-complete unstructured ensemble.  
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Figure 2.3. A. Segment-averaged PF for unmodified p53 NTD. The same data is mapped onto 
the 3D structure on the right. Regions with high helical propensity are shown in red cylinders 
aligned with the sequence domains with PF of 2 or higher containing some residual structures. B. 
Segment-averaged PF for phosphop53 NTD. The PF data is also mapped onto the 3D structure 
on the right. 
 
Although there was an overall increase in deuterium uptake for modified p53 NTD, the 
C-terminal helix was protected as exhibited by lower deuterium uptake in the kinetic data 
compared to the rest of the regions throughout all of the time points which strongly suggests 
stabilisation of the C-terminal helix upon phosphorylation (Figure 2.4). Such local stabilization 
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could play a critical biological role as it allows for the exposure of other linear motifs within the 
NTD and may facilitate binding with other interating proteins. Based on HDX and IMS data, 
native and phosphop53 both exhibited distinctive differences in dynamic behaviours in solution. 
Native p53 NTD exhibited a partially collapsed conformation with the presence of transient 
helical structures172. However, upon phosphorylation, there was an extension of the overall 
conformation with stabilisation of the C-terminal helix. These distinctive dynamics may also 
provide evidence for discrepancies in Kd values when binding to the PH domain and insights to 
p53 being a central hub to its transcriptional activity network.  
 
 
Figure 2.4. Kinetic plots for three sample peptides. 3-29 (3xPhos), 18-47 (3xPhos), and 44-52. 
Dashed lines represent the intrinsic rate kinetics of the labeled peptides and solid lines represent 
the experimental data kinetics observed at 3 or more labelling times (n = 3), error bars represent 
S.E. 
 
2.3.2 p53-PH and phosphop53-PH complex 
 To investigate the effect of phosphorylation in p53 NTD complexation, the interaction 
between the (un)modified p53 NTD with PH domain was examined.  p53 NTD and PH domain 
were incubated in equimolar concentrations to achieve complex formation and this was validated 
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using SEC-MS and native agarose gel (Figure 2.5). During SEC-MS, MS did not detect the 
complex as a whole but rather as individual components suggesting dissociation of the complex 
during the separation process. Free p53 NTD eluted at a retention time of 53.46 minutes and free 
PH eluted at 51.4 minutes. Bound p53 NTD of the complex eluted at 51.2 minutes (Figure 2.5A). 
The fact that bound p53 NTD eluted earlier than the free p53 NTD validated complex formation 
despite its dissociation during the separation process in the column175. This was further supported 
by the native agarose gel electrophoresis in Figure 2.6B. 
 
Figure 2.5. A. SEC-MS chromatogram for free p53 NTD (solid black line), free PH (solid 
red line), and p53 NTD in complex (dashed blue line). A BioSep S4000 column was used with 
an internal BSA standard (data not shown). Free p53 NTD and PH eluted at 53.46 and 51.4 
minutes respectively, whereas bound p53 NTD eluted at 51.2 minutes. B. Native agarose gel 
electrophoresis showing the migration of free p53 NTD and PH as well as the complexes at 
varying ratios.  
 
Next, the binding site of the complex was determined using TR-HDX and compared with 
literature data. Equimolar concentrations of 50µM were used to form the complex and the HDX 
conditions were kept constant as per native p53/phosphop53 TR-HDX. Figure 2.6 shows the 
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segment-averaged deuterium uptake difference plot of the (un)modified complex and 
(un)modified p53 NTD at 0.95s. Difference plot of  native complex and free p53 NTD showed 
that residues 18-31 and 37-43 exhibited a decrease in deuterium of 2.5 to 5% upon binding to 
PH. However residues 44-52 exhibited a drastic decrease of 5.5% in the C-terminus. This data is 
in agreement with previous literature data where residues 47-55 were determined to be the 
binding site using NMR spectroscopy134. HDX on the phosphop53-PH complex was then 
conducted. Interestingly, the difference plot of the modified complex and modified p53 NTD 
exhibited a similar HDX profile where residues 18-28, 33-43, and 48-52 exhibited a decrease in 
deuterium of 2.5 to 5% upon binding and residues 31-32 and 44-47 exhibited a decrease of 5.5% 
(Figure 2.6). The data indicate that, unlike the unbound species, the ‘in-complex’ structure of the 
p53 NTD is independent on phosphorylation and that both native p53-PH complex and 
phosphop53-PH complex have similar bound conformations, also suggesting that both complex-
bound ground states are similar thermodynamically.  
To summarize the data, phosphop53 resulted in an increase of disorder upon 
phosphorylation which corresponds to an elevated free energy state configuration relative to the 
native as shown by TR-HDX and IMS data119. This was further supported when the structure and 
dynamics of the unmodified and modified complex bound-states were similar independent of 
phosphorylation. This large energy difference between free native and phosphop53 contributes to 
tighter binding to the PH domain of the p62 subunit. Horn et al. illustrated a very similar case by 
conducting HDX studies on two variants of human growth hormones (wt-HG and v-HG)167. It 
was shown that v-HG was highly flexible and more solvent exposed compared to wt-HG. 
Interestingly however, v-HG exhibited a 400 fold increase in Kd relative to wt-HG when bound 
to HG cognate receptor. Furthermore, both variants’ bound states were similar 
 
 
54 
 
thermodynamically, similar to the case of p53-PH domain complex167. An elevation of the free 
phosphop53 ground state points toward an increase in binding affinity without lowering the 
energy of the phoshop53-PH complex. Furthermore, Borg et al. also demonstrated an increase in 
binding affinity of IDPs using a “polyelectrostatic” model which suggested that incorporation of 
multiple charges such as phosphates on a disordered protein can influence its binding affinity 
towards its partner through net charge effects. Specifically they showed that by altering the net 
charge of cyclin dependent kinase inhibitor Sic1 from -1 to -6 (increase in phosphate 
incorporation), it enhanced its binding affinity towards Cdc4 by 100 fold (100 to 1μM)176. 
 
 
Figure 2.6. Difference HDX plot of unmodified complex with free p53 NTD (black dotted 
line) and phosphorylated complex with phosphorylated p53 NTD (gray dotted line) at 0.95s 
of mixing. Same HDX data is mapped onto the 3D structure shown on the right. 
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2.4 Conclusion 
Despite the unstructured nature of native p53 NTD, it still retains a partially collapsed 
state with the presence of transient helices. Extended conformation of p53 upon phosphorylation 
not only exposes linear motifs allowing for other proteins to bind for the activation of cellular 
responses, but also enhances binding affinity to PH domain via a higher ground state energy 
difference. Despite this enhanced binding affinity, the bound energy states of both native/PH 
domain and phosphop53/PH domain complexes do not change. HDX and IMS analysis of native 
p53 NTD, phosphop53, native p53-PH complex and phosphop53-PH complex are powerful 
complementary techniques highlighting the importance of protein dynamics in molecular 
recognition especially for disordered proteins and/or domains. 
 
2.5 Materials and Methods 
2.5.1 Protein expression and purification. p53 NTD- pET28a construct and Chk2- pET28a 
plasmids were kindly provided by Dr. Yi Sheng (York University). PH domain was cloned from 
pDONR223 plasmid encoding general transcription factor II H, polypeptide I gene into 
pGEX4T2 plasmid. The proteins were bacterially expressed and further purified using Ni 
Sepharose 6 Fast Flow resin (p53 NTD and Chk2) and Glutathione Sepharose 4B resin (PH-GST 
construct). Subsequently, the proteins were concentrated using Vivaspin concentrators and buffer 
exchanged using Zeba desalting columns to remove high concentrations of imidazole or reduced 
glutathione. 
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2.5.2 In vitro p53 NTD phosphorylation. p53 NTD phosphorylation was carried out by 
incubating 70uM of p53 NTD with 10uM of Chk2 kinase in phosphorylation buffer (50mM Tris-
HCl (pH 7.5), 10mM MgCl2, 5mM DTT and 3mM ATP) for two hours. The kinase was 
deactivated by boiling the reaction at 80°C for 5 minutes, the precipitated kinase was then 
centrifuged and discarded. 
2.5.3 Phosphopeptide identification and localization. The reaction was digested in the 
presence of pepsin agarose for 20 minutes at room temperature. Subsequently, the digested 
peptides were desalted and phosphopeptides were enriched using titanium dioxide resins. The 
phosphorylation sites were further identified using MS/MS or LC-MS/MS. 
2.5.4 In vitro binding studies. To determine the binding of p53 NTD to PH domain, proteins 
were incubated in equimolar concentrations (50uM:50uM) overnight at 4°C. 30uL of the reaction 
was then loaded on BioSep-SEC-S4000 HPLC column (5uM resin) coupled to the mass 
spectrometer along with 5uM of internal BSA standard. Separation was performed at a flow rate 
of 0.2ml/min in SEC buffer (200mM ammonium acetate, pH 7.5) with a method time of 60 
minutes.  
2.5.5 TR-HDX chip fabrication. The microfluidic device was constructed as previously 
described with few modifications 72. The rapid mixing device and acid quenching lines were 
connected using a Valco t-mixer externally. The output of the Valco t-mixer was then connected 
to the PMMA chip for infusion into the digestion chamber. Protein and deuterium were mixed at 
a 1:1 ratio at flow rates of 2:2 ul/min. Acid flow rate was 12 ul/min. All of the experiments were 
done in triplicates. 
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Chapter 3 
Hyperphosphorylation of Intrinsically Disordered Tau 
Protein Induces an Amyloidogenic Shift in Its 
Conformational Ensemble 
 
A version of this chapter was published in PLoS One:  
 
 Zhu, S.; Shala, A.; Bezginov, A.; Sljoka, A.; Audette, G.; Wilson, D. J. 
Hyperphosphorylation of Intrinsically Disordered Tau Protein Induces an Amyloidogenic 
Shift in Its Conformational Ensemble. PLoS One. 2015, 10 (3), e0120416. 
 
3.1. Summary 
Tau is an IDP whose primary function is to stabilise microtubules in neuronal axons 
maintaining the cell’s morphology. In AD and other taupathies, however, tau forms insoluble 
amyloids known as NFTs as a result of hyperphosphorylation of tau monomers. Hence, accurate 
characterization of these “misfolded” intermediates upon hyperphosphorylation is crucial in 
elucidating the structural factors driving tau pathology as well as the rational design of potential 
drugs that could inhibit such formation.  However, IDPs pose challenges to structural biologists 
as they are not amenable to conventional structural biophysical techniques. In this work, TR-
HDX is implemented to study the residual structures in tau as well as the conformational shift 
upon tau hyperphosphorylation. By comparing the unmodified and modified ensemble, a specific 
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conformational bias was defined that provided the structural implication for the enhancement of 
amyloidogenic propensity. Representative structures for both native and hyperphosphorylated tau 
were generated using a low computational modeling approach that is in agreement with the TR-
HDX profiles.  
 
3.2. Introduction 
The physiological function of full length tau (htau40) and it’s isoforms is to bind to 
microtubules, thus stabilizing the cytoskeletons of neuronal cells177,178. Tau is of great interest as 
it was found to be one of the hallmarks in AD (the other being dysfunction of Aβ peptide) as 
well as its role in other neurodegenerative disorders such progressive supranuclear palsy, 
Parkinson’s disease and frontotemporal dementia known as tauopathies90,179. There have been 
numerous studies on Aβ and it is also becoming evident that misregulation of tau, such as 
erroneous PTMs, is involved in AD pathology, however, the mechanisms behind its driving force 
is poorly understood90,180,181. Nevertheless, formation of amyloids as a result of misfolded tau 
and Aβ seems to be a common theme in AD. For tau, hyperphosphorylation by GSK3β has 
emerged as a common occurrence in AD182–184. However, without structural information of 
hyperphosphorylated tau, it remains elusive whether this state is a causative agent or a protective 
mechanism against early toxic prefibrillary aggregates180,182,185,186. 
IDPs and IDDs have been a challenge to structural biologists as they are not amenable to 
the current gold standard biophysical techniques such as X-ray crystallography and NMR88. IDPs 
and IDDs often fail to crystallise for X-ray diffraction purposes and due to its lack of well-
defined native structure, NMR signals often broaden out and are clustered in a narrow chemical 
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shift window making its analysis extremely challenging187. Nevertheless, small IDPs can be 
studied by NMR for identification of transient residual structures that have implications in 
binding to biologically relevant partners and probing weak tertiary structures188,189. However, 
studying larger IDPs (>200 residues) can be exceedingly challenging189. 
In this work, a “bottom-up” TR-HDX workflow on a microfluidic platform is 
implemented to probe residual structures and conformational shift in native and 
hyperphosphorylated tau upon GSK3β phosphorylation to better understand tau pathology from a 
structural perspective. Unlike conventional HDX, TR-HDX is highly sensitive to weak hydrogen 
bonding and solvent accessibility making it an ideal candidate for probing transient residual 
structures in IDPs91,190. Data is presented as deuterium uptake as well as PF which is a ratio of 
the peptide’s observed rate and its equivalent random coil intrinsic rate on the millisecond 
timescale. Exposed regions would have higher deuterium exchange and a rate that is closer to its 
intrinsic rate (lower PF) whereas transiently protected regions will have an attenuated deuterium 
uptake and hence lower rate (higher PF).    
 
3.3. Results and Discussion 
3.3.1 TR-HDX on native tau 
IDPs such as tau are difficult to study using conventional high resolution biophysical 
techniques hence alternative low to mid resolution techniques were implemented to study these 
proteins. For example, CD measurements established that tau lacked a stable secondary structure 
and radius gyration analysis by small angle X-ray scattering (SAXS) also confirmed presence of 
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little to no tertiary structures191. Förster Resonance Energy Transfer (FRET) measurements 
suggested a conformational ensemble that resembles a “paperclip-like S” global fold where the 
N- and C-termini are transiently interacting with the repeat domains141,192 . In 2009, Mukrasch 
and colleagues provided the most detailed structural data on native tau using NMR. Despite the 
challenges associated with peak assignments and low spectral dispersion, they were able to 
assign locations of potential residual secondary structures.  With implementation of TR-HDX, 
we provide the first detailed view of the tertiary structural biases in the native and 
hyperphosphorylated tau ensemble. 
The protein and D2O were injected at flowrates of 1µl/min and 3µl/min respectively in 
the rapid mixer to achieve a maximum label of 75% (1:3). The labelled protein is then quickly 
quenched by acetic acid at pH 2.4. The average residence time of the labeled protein in the 
proteolytic chamber ranges between 6-8 seconds. The resulting digested peptide profiles for 
native and hyperphosphorylated tau produced 77.1% and 71.7% sequence coverage respectively 
(Figure 3.1). The full list of digested peptides for native and hyperphosphorylated tau are listed 
in Table B1 in Appendix B. There were a total of 75 peptides from the native protein and 71 
from phosphotau. Although pepsin is known to preferentially and efficiently cleave peptidic 
bonds of bulky hydrophobic residues, the linear shape of the digestion profiles (Figure 3.1B and 
C) indicates it can non-specifically cleave charged residues as well193. There were 19 
phosphorylation sites in the phosphotau peptide list, with five that could not be localised by 
MS/MS (Table B1 and Figure B1 in Appendix B).  
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Figure 3.1. TR-HDX microfluidic chip with native and hyperphosphorylated tau digestion 
profiles. A. Schematic depiction of the TR-HDX microfluidic chip using “bottom-up” workflow. 
Inset shows the rapid mixer composed of two concentric capillaries, protein is introduced in the 
glass capillary (yellow) and D2O is introduced at the gap between the glass and metal (light grey) 
capillaries. Both solutions mix efficiently at the notch region, labeled as mix. Different mixing 
times can be achieved by adjusting the position of the glass capillary. After the labeling step, the 
solution is then quenched at the junction of the rapid mixer and the “acid quench” line with 
acetic acid followed by digestion in the proteolytic chamber. The resulting peptides are then 
electrosprayed into the mass spectrometer. B and C. Digestion profile for native and 
hyperphosphorylated tau respectively. There were total of 75 peptides from the native and 71 
peptides from hyperphosphorylated tau. Adapted from Zhu et al70. 
 
Figure 3.2 shows the process of TR-HDX data analysis for four sample peptides. Figure 
3.2A shows mass spectra of deuterated peptides at the corresponding labeling times and the 
deuterium uptake for each is determined by fitting observed isotopic distributions to theoretical 
values generated by a custom built program72. The best fit distributions are shown as filled black 
dots with the associated deuterium uptake percentage. Once deuterium uptake for all time points 
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are analysed, a kinetic plot is generated as a function of mixing times, as shown in Figure 3.2B. 
In a well-folded protein, the deuterium uptake kinetic plots can often exhibit “bi-phasic” 
behaviour corresponding to both structured and unstructured regions 91. However, in this case, all 
of the kinetic plots fit to a single exponential function, which is not surprising due to the 
intrinsically disordered nature of tau. By dividing a peptide’s intrinsic rate, kint and observed rate, 
kobs, PF’s can be deduced as listed in Figure 3.2B. A peptide’s intrinsic rate is dependent on 
primary sequence and can be calculated from a multiexponential function. All the peptides and 
their associated PF are listed in Table B1. In conventional HDX analysis, the first two residues of 
the N-terminal amino acids are assumed to undergo rapid back-exchange (deuterium to 
hydrogen) during the proteolytic step (usually 5 minutes) and are not included in the intrinsic 
rate calculation. However, since the residence time in our proteolytic step is only 6-8 seconds as 
opposed to 5 minutes, we could incorporate the second amino acid of the N-terminus65,72.  
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Figure 3.2. TR-HDX data analysis of native and hyperphosphorylated tau. A. Raw TR-
HDX spectra for four sample peptides at three different mixing times. Each deuterated spectrum 
is fit to the theoretical uptake (filled dots) with corresponding percentage (inset). B. Kinetic plots 
for the respective peptides. Each are plotted to single exponential functions: solid for observed 
profile and dashed for theoretical profile. Adapted from Zhu et al70. 
 
Figure 3.3 shows the deuterium uptake profile for native (top bar graph) and 
hyperphosphorylated tau (bottom bar graph) at 1.52 seconds of mixing time lined up with the 
domain structure derived from the chemical shift analysis by Mukrash and colleagues188. 
Globally, native tau took up much less deuterium than hyperphosphorylated tau exhibiting weak 
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but strong protection throughout the protein. Interestingly, only 6.7% of the covered sequence 
showed negligible PF that is reflective of a random coil whereas 14.6% of the sequence showed 
moderate PF of 10 and higher. There were no regions that exhibited a PF associated with stable 
secondary structures which was to be expected. Overall, PF ranged between 1 to 70 with a global 
average PF value of 8.1, which indicates the presence of a weak internal hydrogen bonding 
network and/or solvent protection consistent with weakly structured globular proteins. When tau 
was allowed to mix with D2O for 10s, the protein was 90% exchanged and under 2 minutes of 
mixing, it was fully deuterated.  
Low deuterium uptake at the N- and C-termini, proline rich and hexapeptide domains are 
in good agreement with the FRET measurements suggesting an S-fold conformation: contact 
between N-terminus to proline domain and C-terminus to repeat domains corresponding to 
hexapeptide motifs one and two (H1 and H2)192. Hexapeptide motifs are mainly comprised of 
hydrophobic residues that have high β-structure propensity and in NFTs, hexapeptides form the 
core of the fibrils194. Hence low deuterium uptake in H1 and H2 can be thought of as a protective 
mechanism against aggregation and is reflective of its non-amyloidogenic nature in native tau. 
Although the HDX data agrees well with global structural data provided by NMR, regions that 
had been predicted to contain residual structures did not show any decrease in deuterium 
uptake188. Especially in the case of the β-strands and the polyproline helices as these do not 
participate in an internal hydrogen bonding network. Only one of the two helices (C-terminus), 
exhibited drasticly low levels of deuterium uptake which is most likely involved in the S-fold 
conformation in its tertiary fold.  
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3.3.2 TR-HDX on hyperphosphorylated tau 
Hyperphosphorylation was achieved by incubating native tau with GSK3β in the 
presence of ATP for 36 hours resulting in a heterogeneous mixture of phosphotau species (23.9% 
of predicted sites for all kinases and 51% for GSK3β only). Figure B1 shows the MS/MS spectra 
of the phosphorylated peptides. Furthermore, Figure B2 shows the denaturing SDS gel migration 
shift of phosphorylated tau after 5 and 30 hours. All of the localised phosphorylated sites match 
the S/T-XXXX-S/T consensus motif for GSK3β except for T69 and S305 which have been 
identified in vitro by Hanger and colleagues149. Many of the phoshorylated sites were also 
epitopes in NFTs aggregates such as S214, S202, S396, and S404195,196. Hyperphosphorylated 
tau was much more amyloidogenic compared to its native state, forming fibrils with NFT 
morphology within 48 hours whereas tau exhibited amorphous aggregates after 8 days (Figure 
B2). 
 Prior to performing TR-HDX, the solution was filtered through 0.2µM filter disks to 
ensure no aggregates were present. Furthermore, TEM was also performed on the filtered 
solution confirming the absense of soluble aggregates. The HDX profile for hyperphosphorylated 
tau at 1.52 seconds is shown in Figure 3.3 (bottom bar graph). Compared to the native profile, 
phosphotau exhibited a drastic increase in deuterium uptake, especially in the N- and C-termini 
and the hexapeptide II region hinting at an extended conformation. Previous low resolution 
structural studies have shown similar findings where there was an overall extension of the tau 
conformation upon hyperphosphorylation197,198. H1 did not show any change whereas residues 
326-352 and 114-124 showed decreases in deuterium uptake. Residues 326-352 harbour repeat 
domains 3 and 4 that are known to bind to microtubules in its native state. Decreased deuterium 
at this region upon hyperphosphorylation could infer to formation of residual secondary structure 
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or could be due to shielding from solvents due to the rearrangement of the tertiary structure. 
Nevertheless, this protection could be linked to tau’s low affinity to microtubule binding upon 
hyperphosphorylation. Residues 114-124 have been shown to contain 18% of the helical 
structure in its native state, however, this was not reflected in our studies188. Interestingly, upon 
hyperphosphorylation this region showed a drastic decrease whereas the adjacent regions showed 
increases in deterium uptake, strongly suggesting a formation of the helical structure in the 
phosphotau ensemble. The regions corresponding to the residual structure on the C-terminus 
showed a similar phenomenon: increase in deuterium uptake. This could be associated with the 
release of the global S-fold conformation. H2 showed the greatest increase in deuterium uptake, 
going from being strongly protected in the native state to almost completely exposed in the 
hyperphosphorylated state. This exposure of H2 could potentially play a role in increased 
amyloidogenic propensity.  
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Figure 3.3. TR-HDX profile for native and hyperphosphorylated tau at 1.52 s of mixing 
lined up with the primary sequence of tau and the domain structure derived from NMR 
chemical shift index analysis188. Native HDX profile is shown in the top plot (black bars) and 
hyperphosphorylated tau HDX profile is shown in the bottom plot (green and blue bars). Blue 
and green bars represent the phosphorylated and non-phosphorylated peptides respectively. Both 
plots are lined up directly below the secondary structure map derived from NMR where yellow 
arrows represent segments with high β-sheet propensity, red cylinders represent regions with 
high α-helical propensity and green cylinders represent transient polyproline helices188. Adapted 
from Zhu et al70. 
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3.3.3 Structure Modelling 
In order to conclusively validate the above assumptions, a molecular simulation was 
implemented to characterize the structural ensemble of native and hyperphosphorylated tau using 
the HDX data. To do so, Framework Rigidity Optimized Dynamics Algorithm New (FRODAN) 
was used to generate theoretical ensembles for both states199. FRODAN can build models by 
exploring broad regions of the conformational space which is critial for IDPs as they also sample 
these wide spaces. To evaluate the structures, Volume-Area-Dihedral Angle Reporter (VADAR) 
was used to calculate the backbone amide solvent accessiblity of the potential models with the 
deuterium uptake in the HDX data200. The degree of the match is determined by the Pearson 
coefficient, R, between the models and the HDX data as shown in Figure 3.4. Figure 3.4A and B 
correspond to models for native and hyperphosphoryated tau respectively. IDPs can sample a 
wide array of different ensembles and this was reflected in the models generated; no single 
model correlated well with the TR-HDX data with Rmax being ~0.3 for both states. Nevertheless, 
the most representative structures generated contained all the features predicted in our qualitative 
HDX data. In the native ensemble, the high ranking models (R>0.275) exhibited compact 
structures with the expected global S-fold and sequesteration of both hexapeptides. In the 
hyperphosphorylated tau ensemble,  the high ranking models (R>0.16) exhibited extended 
conformations as expected with a few structural nodes corresponding to regions with relatively 
low deuterium uptake. Many of these models also showed exposure of H2 and protection of H1.  
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Figure 3.4. Histograms representing candidate structures of both native and 
hyperphosphorylated tau within the FRODAN ensembles that are in good agreement with 
the HDX data. A. Distribution representing native tau ensemble with Rmax=0.3. B. Distribution 
representing hyperphosphorylated tau ensemble with Rmax=0.29. Adapted from Zhu et al
70. 
 
Following the structural ensemble generation, HDX data (Figure 3.3) was mapped onto 
the highest scoring structures (Figure 3.5). Although, the models are not 100% reflective of the 
HDX data, they still provide a detailed and accurate picture of the conformational shift 
underlying the increase in amyloidogenic propensity upon hyperphosphorylation using GSK3β.  
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Figure 3.5. TR-HDX data mapped onto the most representative structures from native and 
hyperphosphorylated tau ensemble. A.  PF was plotted as a rainbow scheme onto the most 
representative structure from the native tau ensemble where blue to red represents highest to 
lowest protection. Native tau exhibited a global S-fold with both hexapeptides protected in the 
core of the protein. B. PF data mapped onto the most representative structure from the 
hyperphosphorylated tau ensemble. Upon hyperphosphorylation, there was an overall extension 
of the conformation with the release of the termini, exposure of H2 and formation of residual 
structures between hexapeptide I and residues 326-336. Adapted from Zhu et al70. 
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3.4. Conclusion 
Many attempts have been made to study large IPDs such as tau, however due to the 
intrinsic nature of these proteins along with technical limitations of high-resolution structural 
techniques, structural biologists have resorted to using low- to medium- resolution techniques 
such as CD, SAXS, floresence, and FRET. In this study, a detailed view of the conformational 
shift of full length tau driven by GSK3β hyperphosphorylation was obtained. There has been a 
debate over whether hyperphosphorylation plays a causative or preventative role in AD, 
however, there is more evidence towards the causative role as many global structural changes 
can be rationalised as increasing amyloidogenic propensity. Our data demonstrated that 
hyperphosphorylation results in release of its native S-fold to a more extended conformation with 
exposure of H2 whereas H1 still remains sequestered. Exposure of H2 could act as a template for 
early aggregation stages. These data provide the structural implication for the causative role of 
hyperphosphorylated tau in AD and also illustrates the power of TR-HDX coupled to a 
microfluidic chip as a powerful analytical technique for studying IDPs for the characterisation of 
pathogenic conformations.  
 
3.5. Materials and Methods 
3.5.1 htau40 protein expression and purification. Tau was expressed and purified as 
previously reported with minor changes43. Briefly, pET-29b plasmid containing htau40 construct 
was transfected into E. coli BL21 cells for protein expression. Bacteria were grown at 37°C and 
was induced with isopropyl beta-d-thiogalactopyranoside (IPTG) for an additional 3 hours when 
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OD600 was between 0.5-0.8. Cells were pelleted using centrifugation at 6000xg for 30 minutes at 
4°C. The pelleted cells were then resuspended in resuspension buffer: 20mM MES, 0.2mM 
MgCl2, 5mM DTT, 1mM PMSF, pH 6.8. Resuspended cells were then sonicated on ice for 20 
minutes at 15s on/30s off. The sonicated lysate was then boiled for 20 minutes to rid of other 
proteins apart from tau. The boiled lysate was then centrifuged at 40,000xg for an hour at 4°C to 
pellet cell debris and denatured proteins. The supernatant containing tau was dialysed into cation 
exchange loading buffer (buffer A): 20mM MES, 50mM NaCl, 1mM MgCl2, 2mM DTT, 1mM 
PMSF, pH 6.8. Tau was then purified on an ÄKTA FPLC purifier system using a strong cation 
exchange column (SP sepharose FF). Unbound proteins were washed away using 5 column 
volumes (CV) of buffer A. Other proteins were washed away at increasing salt concentrations. 
Tau protein eluted between 150mM to 250mM NaCl. Purified tau was pooled and concentrated 
to ~500µM using Vivaspin concentrator tubes. Finally, the stock protein was aliquoted and 
placed at -80°C for long term storage.  
3.5.2 GSK3β protein expression and purification. GSK3β-pGEX plasmids were kindly 
provided by Dr. Jim Woodgett. Expression was similar to htau40 with minor modifications201. 
The pelleted cells were resuspended in wash buffer: 30mM Tris-HCl, 100mM NaCl, 0.1mM 
EGTA, 0.1mM EDTA, 0.25mM DTT, pH 7.3. Lysates were prepared from sonication which 
were subsequently pelleted at 40,000xg at 4°C. The supernatant containing GSK3β was then 
loaded onto a GST-gravity column. Unbound proteins were washed away with 5 CV of wash 
buffer. GSK3β was eluted using wash buffer with 10mM reduced glutathione. The eluted protein 
was concentrated and buffer exchanged using wash buffer to remove the glutathione. The stock 
protein was then aliquoted and stored at -80°C with an additional 20% of glycerol. 
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3.5.3 Tau phosphorylation in vitro. Purified tau was incubated with GSK3β (20:1 respectively) 
in phosphorylation buffer containing 50mM Tris-HCl, 10mM MgCl2, 5mM DTT and 3mM ATP, 
pH 7.5 at 30°C for 30 hours149,202.  
3.5.4 Transmission Electron Microscopy (TEM) analysis of tau fibrillary aggregates. Native 
and hyperphosphorylated tau were incubated for 8 days and 48 hours respectively at room 
temperature for formation of fibrillary aggregates. Philips EM201 Accelerating Electron 
Microscopy was used to acquire TEM images. 5µl of protein was blotted on a 100 mesh copper 
grid and were stained with 2% uranyl acetate. TEM was operated at 80kV and images were 
observed under magnification at a range of 30-100k.  
3.5.5 Identification of tau using native MS. Concentrated tau was buffer exchanged into 50mM 
ammonium acetate, pH 7.0 using a 5kDa MWCO dialysis cassette. Buffer exchanged tau was 
further diluted with ddH2O reaching a final concentration of 20µM and identified using the 
Synapt G1.  
3.5.6 Fabrication of TR-HDX microfluidic chip. The kinetic mixer and TR-HDX microfluidic 
chip containing the proteolytic chamber were fabricated as previously described with minor 
modifications72,82. Both were fabricated using a VersaLaser via CO2 laser ablation. A proteolytic 
chamber with dimensions of 28.5mm x 4.9mm x 0.4mm was etched on a poly(methyl 
methacrylate) (PMMA) chip. Rapid mixer and acid quenching capillaries were integrated by 
soldering them onto the chip at the microchannels. Pepsin agarose was activated in 1M HCl for 
an hour and was subsequently distributed evenly onto the proteolytic chamber. A thin silicon 
rubber pad was placed between the chip and a custom built clamp was used to create a tight seal. 
The reactor was then flushed with 10% acetic acid, pH 2.4 to remove residual 1M HCl. The 
setup was interfaced to a QStar Elite QToF. 
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3.5.7 HDX of tau and hyperphosphorylated tau. 1µl/min of the protein (100µM) was mixed 
with 3µl/min of D2O in the rapid mixer, achieving mixing ratio of 1:3. Mixing times between 
42ms to 12s were achieved by manually adjusting the position of the mixer. The labelled protein 
was quenched efficiently by acetic acid at the junction of the microchannel, and subsequently 
digested in the proteolytic chamber. To localise the phosphorylation sites, hyperphosphorylated 
tau was tryptically and/or peptically digested. The phosphopeptides were then purified and 
enriched using the Pierce TiO2 Phosphopeptide Enrichment Kit followed by MS/MS. 
3.5.8 HDX and kinetic analysis. The deuterium uptake of individual peptides were calculated as 
a percentage using a custom built FORTRAN software. Theoretical intrinsic rates of the 
corresponding peptides were calculated using an online web tool called Sphere56. The observed 
and intrinsic deuterium uptake at different time points were plotted to yield kinetic data. All of 
the deuterium uptake profiles of individual peptides were fit to single exponential functions to 
generate observed, kobs and theoretical, kint rate constants. The ratio of the rate constants, kint/kobs 
yields a PF for each peptide which is a semi-quantitative measurement that illustrates the degree 
of protection of a particular peptide segment in the conformational ensemble. It is unclear what 
the effect of phosphates has on the HDX rates hence phosphopeptides containing more than 25% 
contribution from backbone amides adjacent to phosphorylation sites are neglected. 
3.5.9 Structure Model. PDB file of the native tau structure derived from NMR studies were 
kindly provided by the Zweckstetter group188. Using this as a template, an initial native tau 
structure was generated based on the Pearson coefficient of the comparison between the TR-
HDX data and calculated solvent accessibility. The hyperphosphorylated tau structure was then 
generated using the selected native structure with the highest Pearson coefficient by forced 
backbone intermolecular repulsion. The resulting PDB files were then translated using MMTSB 
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and WHATIF server was used to add the hydrogen atoms. FRODAN v1.0.1 was implemented 
for molecular simulation which generated ~30,000 candidates. Whenever RMSD reached 1.0Å, a 
PDB snapshot is created. For each snapshot, accessible surface area (ASA) was then calculated 
using VADAR v1.4 using backbone nitrogen atoms only. N-terminal residues exhibited high 
ASA values hence was excluded from the calculation. The quality of the ASA calculation was 
evaluated using the Pearson correlation coefficient again. 
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Chapter 4 
Time-Resolved Hydrogen Deuterium Exchange (TR-HDX) 
Reveals the Structural Basis of Amyloidogenesis Inhibition 
of Tau Protein by Alzheimer’s Drug Candidates. 
 
A version of this chapter has not been published yet 
 
 Zhu, S.; Deng, B.; Sweeting, B.; Taylor, M.; Reed, M.; Wilson, D. J. Time-Resolved 
Hydrogen Deuterium Exchange (TR-HDX) Reveals the Structural Basis of 
Amyloidogenesis Inhibition of Tau Protein by Alzheimer’s Drug Candidates. 
 
4.1. Summary 
Many current drug developments towards AD are driven solely at targeting Aβ, however, 
it is becoming evident that both Aβ and tau act synergistically towards the pathology of AD. 
Hence, one approach would be to target both proteins simultaneously. In collaboration with 
Treventis (a Toronto based biotechnology company), we employed TR-HDX to investigate the 
influence of six potential tau drug candidates on their anti-aggregation mechanism as well as to 
probe their binding sites. Our findings indicated that all six drugs were bound to one of the two 
aggregation prone regions, hexapeptide II. Furthermore, drugs with stronger potency induced 
tighter core collapse of tau upon binding. With the detailed structural information provided here, 
we can refine and improve the potency of next generation drugs targeting AD.  
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4.2. Introduction 
AD is a chronic neurodegenerative disease that mainly affects the elderly and poses one 
of the greatest health care challenges of the 21st century203,204. The two hallmarks of AD are the 
formation of extracellular amyloid plaques (misfolding of Aβ) and intracellular formation of 
NFTs as a result of hyperphosphorylated tau protein145. Thus far, there have been great strides in 
designing drugs to temporarily alleviate the symptoms of the disease such as cholinergic 
drugs205–207. However, there remains an urgent need for an effective therapy204. Much of the drug 
development in this field, whether its small molecule drugs or antibodies for immunotherapy, is 
driven by the amyloid hypothesis mainly targeting Aβ pathology. However, there is increasing 
evidence that Aβ and tau protein do not act in isolation but synergistically and that it would be 
more beneficial to target both proteins simultaneously208,209. For example, immunotherapies 
targeting Aβ alone yielded less than desired results as many showed no efficacy in clinical phase 
III trials despite reducing the Aβ burden, reinforcing the notion that both Aβ pathology and 
taupathies need to be targeted210–212. Tau targeted therapies are still in their infancy with many in 
early clinical phase trials.  Immunotherapy does offer advantages such as guaranteed high doses 
of antibodies with few follow up visits. However, administering the right doses with minimal 
adverse effect can be challenging, time consuming and costly. An alternative approach would be 
the rational design of small molecules that can target a common epitope sites of metastable 
amyloidogenic intermediates such as for Aβ and tau. Although toxic intermediates from different 
amyloidogenic proteins can be structurally different, they all undergo significant conformational 
changes to form a metastable intermediate with common structural features, such as 
manifestation of aggregation prone regions to self-assemble into amyloids213. For example, 
transthyretin must first unfold to transitions from its native to amyloidogenic states whereas Aβ 
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must fold to exhibit the amyloidogenic conformation213. Hence it may be possible to target all 
amyloids through these metastable intermediates. 
 Many efforts have been taken to accurately characterize misfolded toxic tau and Aβ 
intermediate structures in the hopes of designing anti-amyloid drugs to target not only AD but 
also other amyloidogenic neurodegenerative diseases. However due to the disordered nature and 
size of these proteins, many of the high resolution biophysical techniques such as X-ray 
crystallography and NMR have not been amenable, making rational drug design extremely 
difficult187. It is crucial to accurately determine the structure of these toxic intermediates for 
effective rational drug design. In chapter 3, we implemented TR-HDX on a microfluidic chip 
along with low computational modelling to probe the conformational shift induced by 
hyperphosphorylation of tau by GSK3β70. We were able to provide a detailed snapshot of the 
conformational biases that enhanced tau amyloidogenic propensity. Unlike conventional HDX 
platforms which mainly probe stability of hydrogen bonding networks in well-structured regions, 
TR-HDX is able to probe protein dynamics of weakly structured regions in the millisecond to 
second timescale ideal for IDP structural studies72. 
In this work, we employed TR-HDX MS to investigate the influence of six novel AD 
drug candidates that have been shown to inhibit tau NFT formation in vitro along with a negative 
control shown to have no effect. The data presented here provides detailed structural information 
of tau-drug binding as well as a mode of anti-aggregation mechanism, which can further our 
understanding and improve the potency of next generation drugs to inhibit potentially all 
amyloidogenic neurodegenerative diseases. 
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4.3. Results and Discussion 
There is increasing evidence that Aβ and tau both play a role in AD with Aβ being the 
trigger and tau being the bullet in the disease pathology145. Drug molecules that can target both 
have been suggested to be more beneficial and effective. However, due to the disordered nature 
of tau, it has been challenging for current techniques to gain insights into its three-dimensional 
structural properties. Obtaining structural and dynamic information upon potential drugs binding 
could further refine the drug development stage to generate more potent next generation drugs. 
An alternative strategy, TR-HDX was implemented to probe the binding sites of six potential AD 
drugs as well as their modes of binding.  
Native tau has been shown to have a global S-shaped conformation from both FRET and 
NMR measurements where N and C-termini are transiently in contact with aggregation prone 
regions, hexapeptides I (275-280) and hexapeptide II (306-311) such that those regions are 
protected from solvent exposure188,192. Furthermore, TR-HDX studies from the previous chapter 
has also validated this notion70. 
Prior to conducting TR-HDX on the test compounds, a peptide sequence library was 
established using the same TR-HDX experimental setup to keep the parameters consistent. The 
only difference was using ammonium acetate buffer instead of deuterium. The digested peptides 
were further confirmed by online MS/MS and offline LC-MS/MS. The sequence coverage was 
~70% with the majority of missing peptides resulting from the C-terminus. Our replicated native 
tau HDX profile agrees very well with the previously published global native tau models 
whereby the majority of N-terminus peptides showed a decreased deuterium uptake (~30%) 
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along with the two hexapeptides, especially hexapeptide I (<10%). Most of the C-terminus 
peptides were not covered hence it is difficult to speculate for this region.  
 
4.3.1 Negative control 
First, TR-HDX was conducted on the negative control compound incubated with tau. 
Figure 4.1A demonstrates the difference in deuterium uptake plot (drug bound HDX minus 
native tau HDX) as a function of peptides organised in a sequential manner (N- to C-terminus) 
for two mixing time points: 0.36s (left) and 1.52s (right). The repeat domains of tau are 
highlighted in green bars and the peptides containing hexapeptide I and II are highlighted in 
black rectangular boxes. The criteria for significant change upon drug binding were that the 
differences must be at least 5% or greater and that the difference must also surpass 3σ, standard 
deviation (blue dotted lines). For example, at both mixing time points, peptide 328-336 is 
considered to have undergone a significant change as it showed an increase in deuterium uptake 
of more than 5% and it bypassed the 3σ mark. Figure 1B shows the same difference data mapped 
onto a representative three-dimensional structure of tau70,188. Tau repeat domains and 
hexapeptides are shown in stick and sphere representation respectively. The degree of change is 
labelled as a rainbow colour scheme as shown. Overall, the majority of the sequence covered 
showed no observable differences upon binding to the negative control compound, indicative of 
the same conformational dynamics as the native tau ensemble. Silver staining gel and IC50 by 
Enzyme-Linked ImmunoSorbent Assay (ELISA) (courtesy of Treventis) were also conducted to 
see if there were any aggregation inhibition effects as shown in Figure C1 in Appendix C. In the 
silver staining gel, there was no reduction in the level of aggregates even when the compound 
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was spiked up to 60µM. Furthermore, the ELISA showed an IC50 value of ~400µM indicating a 
negligible inhibition effect.  
 
 
Figure 4.1 HDX difference profiles of tau upon binding to the negative control compound. 
A. HDX difference plot at two mixing time points (0.36s and 1.52s). Tau repeat domains (R1-
R4) are shown in green bars and hexapeptide regions are highlighted in black rectangular boxes. 
Blue dotted lines represent the 3σ threshold. B. HDX data plotted onto the representative 
structure of tau with differences highlighted in simplified rainbow scheme colours as shown.  
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4.3.2 TRV-I 
Next, six compounds were tested using TR-HDX under the same experimental 
conditions. The data for these compounds are presented from greatest to lowest potency (TRV-I 
to VI). Figure 4.2 shows the data for TRV-I (most potent compound, IC50~0.71uM) bound to tau. 
Globally, there was an overall decrease in deuterium uptake upon binding to the compound for 
both mixing time points. Specifically, residues 288-294 adjacent to hexapeptide I (279-287) and 
residues 299-326 containing hexapeptide II showed the most drastic decreases. As the mixing 
time increased to 1.52s, the degree of global attenuation persisted across the sequence except for 
residues 299-326 (-17% to -14%). Translating these data onto 3D structures (Figure 4.2B), 
hexapeptide II remained sequestered at both mixing time points. The core of the protein 
(peptides 28-54 and 157-187) at 0.36s of mixing showed a decrease in deuterium uptake of more 
than 10% (highlighted in blue). However, as the mixing time increased to 1.52s, the effects were 
less drastic as demonstrated in green. The data suggests that the compound is binding to the 
hexapeptide II region and subsequently induces conformational change, specifically collapse of 
the core. This collapse may help retain hexapeptide II in the core hence preventing or slowing 
down the aggregation process. A follow-up binding experiment was performed by incubating tau 
with synthetic peptide 306-336 and the binding was validated by native MS. IC50 value for this 
compound was ~0.71µM and its inhibition effect was also reflected in the silver stain gel (Figure 
C1); as the concentration was spiked, the total level of aggregates decreased demonstrating its 
efficacy.  
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Figure 4.2 HDX difference profiles of tau upon binding to TRV-I. A. HDX difference plot at 
two mixing time points (0.36s and 1.52s). Tau repeat domains (R1-R4) are shown in green bars 
and hexapeptide regions are highlighted in black rectangular boxes. Blue dotted lines represent 
the 3σ threshold. B. HDX data plotted onto the representative structure of tau with differences 
highlighted in simplified rainbow scheme colours as shown.  
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4.3.3 TRV-II 
When tau was incubated with TRV-II (IC50~2.42µM, Figure C1), resulting HDX profiles 
for both time points were similar to HDX profiles for TRV-I where there was an overall global 
decrease in deuterium uptake as shown by Figure 4.3. However, there were some noticeable 
differences; for example, at 0.36s of mixing with D2O, only the core of the protein, specifically 
peptide residues 25-96 and 157-209 showed a decrease in deuterium uptake of more than 10%. 
Hexapeptides I and II were not sequestered as they were within 3σ rendering them insignificant. 
Interestingly, as the mixing time increased to 1.52s, two peptides 279-287 and 299-326 
harbouring both hexapeptides I and II respectively, exhibited a decrease in deuterium uptake 
(slightly more sequestration of hexapeptide I) along with the core. One speculation of why 
sequestration of the hexapeptides occurs at later mixing times could be due to weak binding of 
the molecule which is also demonstrated by the “flattened” IC50 curve (Figure C1). To test 
whether TRV-II also binds to hexapeptide II, a similar binding experiment was conducted as 
TRV-I and the resulting native MS confirmed their binding. This supports the notion that TRV-II 
is a weak binder but more interestingly, that the allosteric effects are much greater. Although 
such scenarios are uncommon, Li and colleagues showed somewhat similar results when 
phenylalanine hydroxylase became more dynamic upon binding to its substrate, phenylalanine, 
in its active site along with allosteric effects214. The active site did not exhibit a decrease in 
deuterium uptake upon binding but instead showed a drastic increase214. In their case, they used a 
substrate that was rapidly turning over, here we used an inhibitor that was rapidly yet weakly 
binding (high koff). To fully validate this hypothesis, Isothermal Titration Calorimetry (ITC) 
could be performed to extract the kinetic binding constants.   
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Figure 4.3 HDX difference profiles of tau upon binding to TRV-II. A. HDX difference plot at 
two mixing time points (0.36s and 1.52s). Tau repeat domains (R1-R4) are shown in green bars 
and hexapeptide regions are highlighted in black rectangular boxes. Blue dotted lines represent 
the 3σ threshold. B. HDX data plotted onto the representative structure of tau with differences 
highlighted in simplified rainbow scheme colours as shown.  
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4.3.4 TRV-III 
Incubating tau with TRV-III also yielded a global decrease in deuterium uptake as shown 
by Figure 4.4. Although TRV-III is less potent compared to TRV-II, their IC50 values are 
comparable: 3.07uM and 2.42uM respectively (Figure C1). However, the degree of global 
decrease seemed more pronounced for TRV-III as shown in Figure 4.4A, residues 28-54, 67-96, 
and 157-209 were sequestered to more than 10% in deuterium uptake. Furthermore, hexapeptide 
II (residues 299-336) showed the most drastic decrease in deuterium uptake for both time points 
(~ -30%). This strongly suggests that TRV-III binds to the hexapeptide II region which was 
subsequently verified using native MS. Hexapeptide I also exhibited a decrease in uptake but to a 
lesser extent and only at an earlier mixing time point, indicative of transient sequestration. As 
mentioned earlier, TRV-II and TRV-III’s IC50 values are comparable however the HDX profile 
for TRV-III showed a greater core collapse upon binding. Furthermore, the IC50 curve for TRV-
III is steeper than that of TRV-II’s suggesting that TRV-III might be a better aggregate inhibitor 
than TRV-II (Figure C1). This is shown in Figure 4.4B where the degree of core collapse is 
almost identical to that of TRV-II, but with the hexapeptide II aggregation prone region also 
sequestered in the case of TRV-III.  
 
 
87 
 
 
Figure 4.4 HDX difference profiles of tau upon binding to TRV-III. A. HDX difference plot 
at two mixing time points (0.36s and 1.52s). Tau repeat domains (R1-R4) are shown in green 
bars and hexapeptide regions are highlighted in black rectangular boxes. Blue dotted lines 
represent the 3σ threshold. B. HDX data plotted onto the representative structure of tau with 
differences highlighted in simplified rainbow scheme colours as shown.  
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4.3.5 TRV-IV 
TRV-IV has an IC50 value of 3.6µM (Figure C1) and upon binding to tau, resulted in a 
global decrease in deuterium uptake at both mixing time points resembling data of TRV-III 
bound tau (Figure 4.5A). Similarly, residues 299-326 was the peptide with the greatest decrease 
in deuterium uptake at both time points (Figure 4.5A and B), hinting at the drug binding site 
which has been validated in subsequent binding experiments. At 0.36s of mixing, the core of the 
protein exhibited strong protection against labeling. However, as the mixing time was extended 
to 1.52s, the same change in the core of the protein was attenuated to a lesser extent (5-10% as 
opposed to 10-15%). These data suggest that TRV-IV binds strongly to the hexapeptide II region 
as shown by consistently low deuterium uptake upon binding (residues 299-326). This 
subsequently results in strong core protection of tau rendering it to be less dynamic. However, 
this induced compact conformation was transient as shown by the negligible change in structure 
compared to the native state at 1.52s of mixing (Figure 4.5B). Previous HDX data on the three 
potent inhibitors (TRV-I to III) showed that the induced compact conformation was more 
persistent as shown by continuous attenuation even at 1.52s of mixing.  
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Figure 4.5 HDX difference profile of tau upon binding to TRV-IV. A. HDX difference plot at 
two mixing time points (0.36s and 1.52s). Tau repeat domains (R1-R4) are shown in green bars 
and hexapeptide regions are highlighted in black rectangular boxes. Blue dotted lines represent 
the 3σ threshold. B. HDX data plotted onto the representative structure of tau with differences 
highlighted in simplified rainbow scheme colours as shown. 
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4.3.6 TRV-V 
IC50 conducted on TRV-V resulted in a value of 22.2µM as shown in Figure C1 (much 
weaker than the previous drugs) and the resulting difference HDX plot still showed a global 
decrease in deuterium uptake (Figure 4.6A). Unlike the previous compounds, where the decrease 
was pronounced throughout the sequence, most of the peptides showed less than 10% decrease 
(Figure 4.6A and B). The only peptide that showed consistent protection, although not so strong 
at 1.52s of mixing, was 299-326 (hexapeptide II) which also happens to be the binding site for 
the drug inhibitor. Residues 25-54 and 67-91 of the core showed moderate protection (~ -8%) at 
0.36s of mixing. When the mixing was extended to 1.52s, only residues 67-91 showed 
protection. This indicates that TRV-V is specific but has a high koff  towards hexapeptide II of tau 
which is a common property of IDPs93.  Furthermore, the resulting allosteric effects are not as 
pronounced as the previous drugs which could explain the lower potency of TRV-V. 
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Figure 4.6 HDX difference profile of tau upon binding to TRV-V. A. HDX difference plot at 
two mixing time points (0.36s and 1.52s). Tau repeat domains (R1-R4) are shown in green bars 
and hexapeptide regions are highlighted in black rectangular boxes. Blue dotted lines represent 
the 3σ threshold. B. HDX data plotted onto the representative structure of tau with differences 
highlighted in simplified rainbow scheme colours as shown. 
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4.3.7 TRV-VI 
The last compound, TRV-VI has an IC50 value of 51.34µM (Figure C1). The resulting 
difference in HDX at both mixing times showed an increase in deuterium uptake in many 
peptides upon binding, however they were rendered insignificant as many failed to pass 3σ 
(Figure 4.7A). The only peptide that showed continual decrease was 299-326 which includes 
hexapeptide II. Mapping the data onto the representative 3D structure showed no observable 
conformational changes except for hexapeptide II (Figure 4.7B). Unsurprisingly, this region was 
also the binding site of the drug validated by native MS. TRV-VI only binds to hexapeptide II 
region with high affinity without inducing any conformational changes unlike TRV-I to V hence 
only the aggregation prone motif is sequestered whereas the rest of the protein remains as 
dynamic as native tau.  
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Figure 4.7 HDX difference profile of tau upon binding to TRV-VI. A. HDX difference plot at 
two mixing time points (0.36s and 1.52s). Tau repeat domains (R1-R4) are shown in green bars 
and hexapeptide regions are highlighted in black rectangular boxes. Blue dotted lines represent 
the 3σ threshold. B. HDX data plotted onto the representative structure of tau with differences 
highlighted in simplified rainbow scheme colours as shown. 
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4.4. Conclusion 
When tau was incubated with the negative control compound, there was no observable 
differences in deuterium uptake. However, when incubated with experimental compounds that 
showed aggregate inhibition effects (ELISA and silver staining gel experiments), there were two 
noticeable differences: (1) all the compounds were bound to hexapeptide II motif region 
(confirmed by native MS) and (2) the higher the potency of the drug, the greater the protection of 
the core from deuterium uptake. The least potent drug, TRV-VI, however only showed binding 
to the hexapeptide II region without inducing internal core collapse. The summarized data is 
shown in Figure 4.8. 
Previously, we have shown that upon tau hyperphosphorylation using glycogen synthase 
kinase 3β (GSK-3β), there was a structural ensemble shift from its native global S-fold into a 
more extended conformation with exposure of the hexapeptide II motif to the solvent. This 
release has been implicated in amyloidosis by providing an aggregation template70. The data 
presented in this work agrees very well such that binding of the drugs sequesters hexapeptide II 
and the higher potency drugs induce a stronger internal collapse such that overall extension of 
the conformation is prohibited. Based on the findings, it appears that conformational change 
(internal collapse) upon drug binding plays a bigger factor in the mechanism of anti-tau 
aggregation than simply the drug binding. Perhaps the diminished dynamics along with more 
compact conformations limits its radius of capture and the binding of the inhibitors to 
hexapeptide II prevents the initial “aggregation-priming” step93,215. 
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Figure 4.8 Summarized TR-HDX profiles of six drug candidates as function of IC50 
potency. TR-HDX data plotted onto the representative structure of tau with differences 
highlighted in simplified rainbow scheme colours as shown. Compound names are assigned at 
the bottom of the corresponding structures.  
 
4.5. Materials and Methods 
4.5.1 Protein expression and purification. Tau expression and purification was carried out as 
previously reported70. Purified proteins were concentrated using Vivaspin concentrators which 
were subsequently aliquoted and stored at -80°C. Small molecules were kindly provided by 
Treventis. 
4.5.2 Crosslinking protease XIII to agarose beads. Protease XIII from Aspergillus saitoi was 
crosslinked to N-hydroxysuccinimide (NHS) activated agarose beads with minor modifications; 
linking and quenching buffers were maintained at pH 5.0. Furthermore, crosslinking was 
performed overnight at 4°C.  
4.5.3 TR-HDX microfluidic chip fabrication. The PMMA microfluidic device and rapid 
mixing module were constructed as previously described with a few modifications70,72. Briefly, 
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the proteolytic chamber with a dead volume of 50ul (without the addition of crosslinked protease 
XIII to the agarose beads) was etched on the device using CO2 laser ablation. The rapid mixing 
module and acid quench lines were connected using a Valco stainless steel T-mixer externally. 
The output of the Valco mixer was then connected to the proteolytic chamber using a stainless 
steel capillary. A thin silicone rubber pad was interfaced between the active and blank PMMA 
chip to create a tight seal using custom built clamps. The chip was then interfaced with a QTOF 
mass spectrometer. 25uM of tau was buffer exchanged into 100mM ammonium acetate buffer, 
pH 7.0. Subsequently desalted tau was then pre-incubated with 50uM of small molecule for one 
hour at room temperature prior to the HDX experiments. Protein and deuterium were mixed at a 
1 (2ul/min):1 (2ul/min) ratio. Acid flow rate was 12ul/min. Labelling times ranging from 320ms 
to 3s were achieved by manually adjusting the position of the mixer. All the experiments were 
conducted in triplicates. Custom-built software was used to analyse raw TR-HDX data. 
4.5.4 MS binding studies. For native MS binding assays, 25uM of tau in ammonium acetate 
buffer, pH 7.0 was incubated with 50uM of compound for an hour at room temperature. 10% 
acetonitrile was added to the solution prior to native ESI-MS. 
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Chapter 5 
Differential Mobility Spectrometry-Hydrogen Deuterium 
Exchange (DMS-HDX) as a Probe of Protein Conformation 
in Solution 
 
A version of this chapter was published in Journal of the American Society for Mass Spectrometry:  
 
 Zhu, S.; Campbell, J.L.; Chernuschevich, I.; LeBlanc, J.C.Y.; Wilson, D. J. Differential 
Mobility Spectrometry-Hydrogen Deuterium Exchange (DMS-HDX) as a Probe of Protein 
Conformation in Solution. J. Am. Soc. Mass Spectrom.. 2016, 27 (6), 991-999. 
 
5.1. Summary 
DMS, a variant of IMS technology is routinely used to pre-filter and study small 
molecules from complex mixtures. However, application of DMS to study larger 
macromolecules such as proteins remains unexplored apart from its analogue, FAIMS. In this 
work, DMS combined with gas-phase DMS-HDX is employed to probe the gas-phase 
conformations of folded, unfolded, and partially folded proteins in solution. With optimised 
conditions, our findings suggest that proteins with distinct structural features in solution 
exhibited unique DMS-HDX profiles. Although the results provided in this study give a coarse-
grain picture of the global protein features, with proper implementation this technique can be 
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utilized as a rapid qualitative assay to characterize structural stability of proteins in solution that 
could be of use in biopharmaceutical settings.  
 
5.2. Introduction 
IMS is routinely used in the field of MS to separate gas-phase ions based on their CCS 
areas. It is increasingly adopted in the field of structural biology for separation and analysis of 
protein structures, dynamics, and complex macromolecular topologies13,216. DMS is a variant of 
the IMS approach that acts as a pre-filtration mechanism of small molecules in atmospheric 
pressure prior to entering the mass spectrometer26,217. Post ionization, ions are pre-selected based 
on the difference between their high- and low- field mobilities defined as ΔK. To achieve such 
separation, an asymmetric rf voltage known as the SV is applied orthogonal to the direction of 
the ion flow which subsequently results in a net displacement trajectory of the ions. It is possible, 
however, to nullify such lateral displacement for individual ΔK by applying a specific DC offset 
known as CV, allowing a stable trajectory through DMS into the mass spectrometer21,26.  
One characteristic difference for this approach compared to the conventional drift tube or 
TWIMS is that the separation parameter, ΔK, is influenced by various factors that are intrinsic to 
the molecule rather than simple CCS areas. For example, interactions of the modifier (transport) 
gases with molecules of varying properties such as polarity and size can have a substantial effect 
on ΔK. This can be advantageous as various modifier gases, usually volatile chemical modifiers, 
can be optimised and implemented to allow for high resolution separation of species with 
identical CCSs28,218–220. A schematic cross section of DMS is shown in Figure 5.1. Despite its 
high separation capabilities, quantitative measurements such as determination of CCS areas of 
 
 
99 
 
molecules are challenging due to “clustering” effects of the modifier gases as well as other 
factors associated with the alternating fields, especially at high field and temperature. Large 
proteins exhibit strong molecular dipole moments during their transit in DMS due to field 
induced alignment. This can be problematic as the resulting eluted CV profiles show a bimodal 
distribution corresponding to folded and unfolded (field induced) conformations24,30. However, 
this effect is negligible for smaller proteins (<12kDa). Thus, little effort has been made to study 
larger proteins using DMS since the correlation between DMS acquired gas-phase structural 
information was poor compared to the liquid-phase protein ensemble22,29,34,221.  
HDX is a chemical labeling reaction that is dependent on the structure of the protein 
whereby exposed and labile hydrogens undergo exchange with deuterium in the solvent222. 
Unlike liquid phase HDX, where the reaction is predominantly base-catalyzed, the gas-phase 
HDX reaction mechanism is poorly understood223,224. Nevertheless, it is viewed as a sensitive 
probe and has been combined with other mobility techniques such as TWIMS to study gas-phase 
protein structures225,226. Gas-phase HDX has been used in tandem with FAIMS (variant of DMS) 
to characterise different gas-phase protein conformations, with labeling occurring post FAIMS 
separation. Despite separation and characterisation of a multitude of different gas-phase 
conformations, the results were uninterpretable in the context of translating it to the solution 
structure25,34. For example, many of the co-populated conformations within the well folded 
protein exhibited wildly different CV values. It would have been understandable if this was the 
case for unfolded conformations as they can be vastly different.  However, these substantially 
different CV values of the well-folded conformations suggest that much of the heterogeneity 
must have been generated during the FAIMS separation34,227. Thus, FAIMS-HDX has been 
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shown to be a powerful tool to generate and study heterogeneous gas-phase conformations, but 
poor in correlating it to liquid phase structures.  
DMS and FAIMS separation conditions are analogous hence if the labeling were 
performed post separation in DMS (like FAIMS), similar results would be obtained (little to no 
correlation with the solution phase). However, liquid-phase structural information might be 
retained if the labeling occurred simultaneously to the protein separation as it transits through 
DMS. In this report, a set of model proteins were tested using DMS-HDX to determine 
experimental conditions that can ultimately reflect the resulting DMS-HDX profiles to liquid-
phase structures. The model proteins selected encompassed a wide range of solution structure 
characteristics including native cytochrome c and holo-myoglobin (well-folded), 
hyperphosphorylated tau (partially folded), and native tau (intrinsically disordered)70,141. The 
proteins were subjected to and investigated under different sets of instrumental conditions with 
the addition of HDX reagent in the modifier gas and/or throttle gas (DMS/MS interface). 
Ultimately, a set of conditions were determined where DMS-HDX can be used as a rapid yet 
reliable assay for correlating liquid-phase structure information with the resulting DMS-HDX 
profiles.  
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Figure 5.1. Schematic representation of the DMS cell with all the components depicted. 
Adapted from Shneider et al26. 
 
5.3. Results and Discussion 
5.3.1 Tau and hyperphosphorylated tau DMS profiles 
Previously, FAIMS has been implemented to characterise differential mobility profiles 
for well-defined native protein structures such as cytochrome c and myoglobin30,34. However, 
IDPs such as tau are unexplored analytes as no previous studies have been attempted on such 
proteins70,188. Tau is an IDP under native conditions hence can be studied under the same 
conditions as cytochrome c and myoglobin. Its unfolded nature is shown in the DMS-MS 
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spectrum in Figure 5.2A. Wide and high charge state distribution in the mass spectrum is 
characteristic of IDPs. Furthermore, broad DMS profiles for each charge state are also expected 
due to strong pendular alignment effects for large proteins (46kDa) and this was exhibited by the 
bimodal distribution in the CV profile (Figure 5.2A). Initially, different modifier gases were used 
and optimised such that the best DMS separation was achieved for the set of proteins studied. 
Different volatile gases such as methanol and acetonitrile did achieve a certain degree of 
separation, however, it was 1:1 (ND4OD:CH3OD) that achieved the best result across all the 
proteins. Figure D1 shows the effect of different modifier gases on cytochrome c, myoglobin, 
native and hyperphosphorylated tau and is found in Appendix D.  
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Figure 5.2 Ionogram of DMS-HDX profiles for native and hyperphosphorylated tau 
protein. (A) DMS-HDX profile ionogram for native tau protein. DMS profile panel is shown 
above the ionogram and the mass spectrum is displayed in the panel to the right. Inset shows   the 
zoomed in high-charge and low CV regions. (B) DMS-HDX profile ionogram for 
hyperphosphorylated tau protein. DMS profile panel is shown above the ionogram and the mass 
spectrum is displayed in the panel to the right. Inset represents the zoomed in high-charge and 
low CV regions and shows peak splitting upon hyperphosphorylation, indicated by black arrows. 
Adapted from Zhu et al228. 
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Tau hyperphosphorylation by GSK3β induces an overall conformational shift where it 
involves lengthening of the protein with establishment of several structural nodes70. Hence 
hyperphosphorylated tau represents a “partially folded” protein model in this study. The mass 
spectrum resembles native tau as shown by the DMS-MS profile in Figure 5.2B. However, there 
is one observable difference in the high charge/low CV region where the peaks were split into 
two. It could be due to the presence of new structural features (i.e., extended conformation with 
development of structural nodes) or potentially due to the consequence of differing clustering 
behaviour with phosphates. This open interpretation highlights the challenges in drawing 
meaningful conclusions from CV profiles. However, gas-phase DMS-HDX could provide more 
information that can address the issue of whether the separation was structure dependent or due 
to clustering effects. 
 
5.3.2 DMS-HDX on well-folded proteins 
In a typical planar DMS experiment, a transport gas (N2 ) with/without modifier gas is 
incorporated at the entrance of DMS for separation31,229. As for resolution enhancement, a 
throttle gas can be introduced at the interface of DMS and the mass spectrometer orifice26,230. 
HDX reagents can be introduced at these inlets for labeling experiments. Addition through 
transport gas lines enables reactions to occur “in-transit” during the DMS separation whereas 
addition through the throttle gas line enables “pulse labeling” post DMS separation. Few HDX 
studies have been conducted on DMS through the pulse labeling approach (i.e., post DMS 
separation) as this would provide structural insights arising from the separated species. 
Furthermore, this approach is not complicated by the clustering effect in addition to gas-phase 
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HDX while separation occurs. Pulse labeling can be achieved by bubbling HDX reagents such as 
ND4OD or D2O vapors by N2 gas through the throttle gas line.  
Although pulse labeling provides important gas-phase structural information, the HDX vs 
CV profiles exhibited weak correlations between CV and deuterium uptake. For example, 
adjacent charge states of well-folded protein, cytochrome c, showed wildly different CV vs HDX 
profiles. A similar experiment was conducted using ND4OD as an HDX labeling reagent in the 
throttle gas line and the resulting profiles for charge states +6, +7, and +8 were completely 
different as shown in Figure 5.3A and Figure D2 (Appendix D). These data reiterate the fact that 
FAIMS separation with HDX studies yield no interpretable or reliable correlation between gas-
phase and liquid-phase protein conformations25,34,227. Hence it is clear that different 
conformations arising from DMS separations do not retain their solution structure information.  
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Figure 5.3 Mass spectra of native and unfolded cytochrome c with DMS-HDX profiles of 
corresponding charge states. (A) Native cytochrome c spectrum with deuterating agent 
(ND4OD:CH3OD) added in the throttle gas line. Inset shows the DMS-HDX profiles for 
individual charge states. (B) Native cytochrome c spectrum with ND4OD:CH3OD added in the 
transport gas line. Inset shows the DMS-HDX profiles for individual charge states. (C) Acid-
induced unfolded cytochrome c spectrum with ND4OD:CH3OD added in the transport gas line. 
Inset shows the DMS-HDX profiles for individual charge states. Adapted from Zhu et al 228. 
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An alternative “in-transit” labeling approach was implemented where 1:1 
ND4OD:CH3OD was added at 1.5% (v/v) along with N2 in the transport gas line. The residence 
HDX labeling time during transit was ~16ms which is much longer than the sub-ms “pulse-
labeling” in the throttle gas line. The resulting mass spectrum showed a decrease in overall 
charge states, with a substantial increase in deuterium uptake (average deuterium uptake for +6 
cytochrome c was 110). This drastic increase in deuterium uptake is not surprising since ND4OD 
is a much more reactive HDX reagent than D2O. Interestingly, the HDX vs CV profile yielded a 
positive linear correlation for all charge states as shown in Figure 5.3B. Slope values were 1.1 × 
10−2, 1.0 × 10−2, and 1.0 × 10−2 for the +5, +6, and +7 charge states, respectively with R2min = 
0.95. Another interesting observation is that DMS profiles for different charge states of native 
cytochrome c spanned a wide CV range (between 6-16V) representing a broad set of gas-phase 
conformations. However, based on the relative deuterium uptake profile in Figure 5.3B, they are 
all within 0.9-1.0 suggesting similar conformations in this wide CV range. It is somewhat 
expected as native proteins even in their ground state still exhibit some degree of flexibility. 
Although these conformers can be HDX distinct, however, the overall ensembles are very 
similar. To test if this correlation was unique for well-folded proteins in solution, another 
experiment was conducted on native holo-myoglobin. The resulting data yielded the same 
positive linear slope in the HDX vs CV profiles (Figure D3). Hence planar DMS with HDX 
reagents introduced at the transport gas line can be used to provide a coarse-grained picture of 
solution phase protein structure. 
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5.3.3 DMS-HDX on unfolded proteins 
Folded proteins generated a linear sloped HDX vs CV profile. To test if this “in-transit” 
labeling technique can also provide a unique profile for unfolded and partially-folded proteins, 
the same experiment was conducted on acid induced unfolded cytochrome c, IDP tau, and 
molten globular hyperphosphorylated tau. Table 5.1 provides the structural characteristics for 
these model proteins.  
Table 5.1. Overview of the structural and HDX characteristics of model proteins used.  
 
 
Figure 5.3C shows the profile for acid-induced unfolded cytochrome c. Typically 
unfolded proteins exhibit broad, high charge distributions, however, here we observed low 
charge states due to the strong charge stripping effect coming from highly basic ND4OD in our 
1:1 ND4OD:CH3OD modifier gas. This resulted in the shift of charge distribution to lower 
charge states with +5 being the center. Charge stripping was observed for all model proteins but 
was most pronounced for unfolded proteins. Although, the charge state distribution of unfolded 
cytochrome c was similar to native cytochrome c, the resulting DMS profiles were different as 
shown in Figure 5.3C. Unlike native, DMS profiles of individual charge states of unfolded 
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cytochrome c exhibited a flat line with slopes of 1.0 × 10−3 (+5), 1.2 × 10−3 (+6), and 3.5 × 
10−3 (+7), R2min = 0.92. This is not surprising as unfolded species populate a wider 
conformational space higher in the energy folding funnel, yet still exhibit an equivalent ensemble 
which was also reflected in the gas-phase conformers. Although folded and unfolded cytochrome 
c have distinct DMS-HDX profiles, one can argue that the unfolded cytochrome c DMS profile 
could be due to different solvent conditions (i.e., 1% acetic acid, pH 2.4). Hence to explore this 
hypothesis, we conducted the same experiment on IDP tau using the same solvent conditions as 
native cytochrome c. The resulting DMS-HDX profile was essentially flat (Figure 5.4A), similar 
to that of unfolded cytochrome c. This strongly suggests that the “flat” profile is a unique 
characteristic to unfolded proteins, whether it’s induced or native.  
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Figure 5.4 Mass spectra of native and hyperphosphorylated tau with DMS-HDX profiles of 
corresponding charge states. (A) Native tau spectrum with deuterating agent (ND4OD:CH3OD) 
added in the transport gas line. Inset shows the DMS-HDX profiles for individual charge states. 
(B) Partially-folded hyperphosphorylated tau spectrum with ND4OD:CH3OD added in the 
transport gas line. Inset shows the DMS-HDX profiles for individual charge states. Inflection 
point occurred at -10 CV. Adapted from Zhu et al228. 
 
 
111 
 
5.3.4 DMS-HDX on partially-folded protein 
Finally, to investigate the DMS-HDX effect on partially-folded protein, 
hyperphosphorylated tau phosphorylated by GSK3β was used. Previous solution HDX has 
shown that this species is more elongated yet structurally constraint, containing small pseudo-
structural nodes compared to native tau70,197. When subjected to the same “in-transit” DMS-HDX 
conditions, the resulting profiles exhibited a “biphasic” appearance as shown in Figure 5.4B. One 
might speculate that this appearance is due to a saturation effect, however, that is not the case as 
the theoretical maximum for tau is 760 and the exchanged sites were 635 (well below the 
maximum). Thus, this “biphasic” profile strongly indicates a mixture of folded (exchange non-
equivalent) and unfolded (exchange equivalent) states with exchange non-equivalent states 
populating the CV regions between -20 to -10V and the exchange equivalent states populating 
the CV regions above -10V.  
Solution phase conformations may not be the same as the gas-phase conformations as a 
result of the DMS separation shown by the HDX pulse-labeling DMS experiments. It can, 
however, control the set of gas-phase conformers populated during the separation shown by the 
“in-transit” HDX experiment.  This observation is consistent with kinetic energy loss cross 
sectional studies conducted by Wright and co-workers where they reported that gas-phase protein 
ions retain a “memory” of their solution conformations231. By utilising these unique DMS-HDX 
profiles that are characteristics of well-folded, unfolded, and partially folded proteins, one can 
conduct a rapid qualitative assay for studying liquid phase protein stabilities such as mutants and 
post-translationally modified proteins. 
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5.4. Conclusion 
DMS, a variant of IMS technology, has been widely implemented to separate and study 
small molecules such as isobaric or chiral species. However, this technology is still in its infancy 
when it comes to studying intact proteins. In this work, planar DMS-HDX experiment was 
conducted to characterize and compare liquid phase conformational states of native folded, 
unfolded, and partially folded proteins to gas-phase counterparts. Although harsh conditions in 
DMS perturbs the solution structure, our results show and support the notion that gas-phase 
protein ions can preserve a “memory” of their liquid phase conformations under optimised 
experimental conditions, in this case, application of ND4OD:CH3OD (1:1) as a modifier gas in 
the transport gas line. Although the findings in this work provide a coarse-grained picture of 
global folding characteristics, a rapid qualitative assay for protein stability can be achieved with 
further fine-tuning of this analysis. For example, relative conformational stabilities of different 
mutants or post-translationally modified species can be studied using the slopes from DMS-HDX 
profiles.  
 
5.5. Materials and Methods 
5.5.1 Protein preparation and tau phosphorylation. Tau was purified as previously 
reported43,70. Please refer to the Materials and Methods section in Chapter 3 for details. Tau 
phosphorylation was carried out by incubating 100µM of tau with 500 units of GSK3β in the 
presence of 3mM ATP at 30°C for 30 hours. The phosphorylated tau was buffer exchanged into 
50mM ammonium acetate buffer overnight and then filtered through 10kDa MWCO Vivaspin 
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concentrator filters to rid of peptides resulting from protein degradation overnight. Native 
cytochrome c and myoglobin was prepared by dissolving salt-free lyophilised powder into 
50mM ammonium acetate. Unfolded cytochrome c was prepared similarly with addition of 1% 
acetic acid reaching a final pH of 2.6. Tau/phosphotau and cytochrome c/myoglobin was diluted 
to 20µM and 5µM respectively prior to direct infusion into the mass spectrometer. 
5.5.2 DMS and DMS-HDX experimental conditions. All the experiments were conducted on a 
modified quadrupole triple time-of-flight mass spectrometer equipped with a planar DMS 
chamber between the mass spectrometer orifice and ESI source (Figure 5.1)26,232. Modifier gases 
including HDX reagents were incorporated into the transport gas via the curtain gas line at a total 
flow rate of 25L/min and/or through the throttle gas line via bubbling. All samples were injected 
at 7µM/min and ESI voltage was maintained at 4800V with a source temperature of 37°C. 
Nebulizer and auxiliary gas were maintained at a constant pressure of 10 and 80 psi respectively 
for tau and phosphotau, and for cytochrome c and myoglobin it was 10 and 30 psi respectively. 
DMS temperature was maintained at 275°C. SV of 3800V and CV scanning of 0.03V increments 
were used throughout the experiments for all the proteins. There were two types of HDX labeling 
experiments: labeling during separation and labeling post separation. For gas-phase HDX post 
separation, D2O or ND4OD was bubbled in the throttle gas at the interface between the DMS and 
mass spectrometer orifice230.  For labeling during the separation, 1:1 ND4OD:CH3OD modifier 
gas was bubbled at 1.5% (v/v) in the curtain gas line along with N2 gas
230. Analogous 
experiments with non-deuterated counterparts were also conducted. 
5.5.3 Data analysis. PeakView v2.1 was used for data analysis. The mass spectra were averaged 
over 1.0 CV window for tau and phosphotau and 0.5 CV for cytochrome c and myoglobin. For 
example, mass spectrum for tau at CV = 6V is the average between 5.5 and 6.5V.  Smoothing 
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function was used to produce a cleaner spectrum for better analysis and reliability. Poor quality 
peaks were omitted from the analysis. The centroid peaks of the deuterated protein peaks were 
subtracted with the non-deuterated counterpart for determination of deuterium uptake. All of the 
experiments were conducted in triplicates.  
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Chapter 6 
Conclusions and Future Work 
6.1. Conclusions 
The work presented here highlights the importance of MS as a critical analytical 
technique to study IDPs and IDDs which have been a challenge to structural biologists due to 
their inapplicability to conventional biophysical techniques such as X-ray and NMR.  Chapter 1 
focused on the fundamentals of the techniques implemented in this work as well as the concept 
of IDPs and IDDs. Fundamental techniques such as hybrid mass spectrometers, front-end 
separation (LC, IMS and DMS), and HDX for protein labelling are described. This is followed 
by a brief introduction to the fundamentals of p53 NTD and tau protein. 
Chapter 2 focused on the study of how phosphorylation affects structure and 
conformational dynamics of the intrinsically disordered p53 N-terminal domain (p53 NTD) and 
how this modification drives complexation with the PH domain of p62 using TR-HDX. Our 
results demonstrated that phosphorylation did not affect the conformation of bound complex 
(p53 NTD to PH domain) as shown by similar HDX profiles for both unmodified and 
phosphop53 in the bound state. Interestingly, this modification increased the dynamics of free 
p53 NTD in the unbound state. This increase in disorder creates a wider free energy gap between 
the unbound and bound states which could explain the higher binding affinity when p53 was 
phosphorylated. This study demonstrated the power of TR-HDX and IMS as a complimentary 
technique that can be used to highlight the importance of protein dynamics in PTM driven 
molecular recognition for IDDs.  
 
 
116 
 
One of the hallmarks of AD apart from formation of extracellular plaques is the 
formation of intracellular amyloids known as NFTs as a result of tau hyperphosphorylation. 
Hence understanding the conformational shift upon tau hyperphosphorylation is critical in 
elucidating the driving force behind tau pathology. In Chapter 3, TR-HDX and computational 
modeling was implemented to probe this shift in conformational bias upon hyperphosphorylation 
by GSK3β. The HDX profile for native tau was in good agreement with previous NMR and 
FRET data suggesting a paperclip-like “S” shaped fold.  However, upon hyperphosphorylation, 
there were two interesting observations. First is the release of the global “S” fold with the 
formation of new intra-hydrogen bonding networks within the microtubule binding region. 
Second is the exposure of one of the aggregation prone regions, hexapeptide II motif, providing a 
“sticky” template to initiate the aggregation process. The data provided a detailed structural view 
of the causative role of hyperphosphorylated tau in enhancing amyloidosis propensity in AD as 
well as highlighting the power of TR-HDX as a powerful analytical technique in probing 
pathogenic conformational shifts in IDPs such as tau.  
Many of the current drug developments for AD targets Aβ aggregates. However, it is 
becoming evident that misfolded tau is the bullet in AD formation whereas Aβ acts as the trigger. 
Hence designing potent small molecule inhibitors that can target tau or both proteins 
simultaneously is more desirable. In Chapter 4, TR-HDX was implemented to investigate the 
structural effect on tau upon binding to six potential AD drug candidates with varying potencies 
from Treventis (a Toronto based biotechnology company). Our results demonstrated that all six 
drugs were bound to hexapeptide II motif regardless of their potency. Interestingly, however, 
higher potency drugs induced a tighter core collapse of tau upon binding, rendering tau less 
dynamic. Taken together, these results indicated that conformational change (internal collapse) 
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upon drug binding may play a larger role in the anti-tau aggregation mechanism rather than drug 
binding. Perhaps the induced compactness and dynamics upon binding limits its radius of capture 
to aggregate with other tau monomers. Furthermore, molecules binding to hexapeptide II 
prevents the initial “aggregation-priming” step by preventing its exposure. These results once 
again highlighted TR-HDX as a powerful technique in elucidating the anti-aggregation 
mechanism of IDPs. With detailed structural information, drug development stages could further 
refine and improve the potency of next generation drugs targeting AD.  
DMS is mainly used for the pre-filtering of small molecules. However, its application in 
studying biomacromolecules remained unexplored except for its analogue, FAIMS, which is 
widely used to separate and characterize gas-phase protein conformations. Despite numerous 
conformations generated in the gas-phase, these do not truly reflect solution phase structures. In 
Chapter 5, DMS coupled to gas-phase HDX (DMS-HDX) with optimized experimental 
conditions was employed to probe and link gas-phase protein conformations to their liquid-phase 
counterparts. Three different protein models were used: folded (cytochrome c and myoglobin), 
unfolded (acid induced cytochrome c and native tau), and partially folded (hyperphosphorylated 
tau). With incorporation of ND4OD: CH3OD (1:1) as a modifier gas, our results indicated 
proteins with distinct solution phase characteristics exhibited unique DMS-HDX profiles as a 
function of their DMS transmission. For example, unfolded proteins exhibited a “flat” constant 
deuterium uptake profile, folded proteins exhibited a positive linear correlated deuterium uptake 
profile, and partially folded protein exhibited a mixture of the two. This technique with further 
optimization could ultimately be used as a rapid qualitative assay to measure structural stabilities 
of liquid phase proteins and can be useful in biopharmaceutical settings such as studying 
different mutants and post-translational modified proteins.  
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6.2. Future Work 
TR-HDX has proven to be a powerful technique to study IDPs and offers many 
advantages over other conventional structural techniques. TR-HDX can characterise short-lived 
species such as toxic intermediates, as in the case of tau, which are invisible to conventional 
techniques such as NMR, X-ray crystallography, and classical HDX techniques. Furthermore, 
weakly structured regions as well as hydrogen bonding networks of proteins in solution can be 
probed. Despite the attractive advantages, there are several areas that can be further improved to 
elevate our current TR-HDX microfluidic system.  
Currently, this method operates on a continuous flow system without any separation 
capabilities and the resulting mass spectra contain overlapping peptide peaks which can be 
challenging for analysis especially for larger protein digestions. Although, front-end separation 
could be achieved with IMS, gas-phase proton exchange could occur depending on the MS 
system. For example, this is a common occurrence in the ion guide of Waters G2 instruments233. 
An alternative approach is to couple TR-HDX to a DMS system and this could potentially be 
more powerful than IMS in filtering out chemical noise and contaminants. For example, at a 
constant SV of 3800V, PEG contaminants transmit at a CV of 10V whereas peptides can 
transmit anywhere between 0-8 CVs. 
 Another caveat is the need to desalt the proteins into MS compatible buffers such as 
ammonium acetate prior to conducting TR-HDX experiments. The majority of cytosolic proteins 
are soluble at low concentrations; however, transcription factor and membrane-associated 
proteins easily precipitate out in these buffers. Hence it is crucial to retain proteins in buffers 
mimicking their physiological conditions. Wilson and Konermann have demonstrated a rapid 
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desalting process on a microfluidic chip  that is capable of removing salt concentration by one 
order of magnitude234. This can be incorporated onto our microfluidic device prior to the ESI 
needle to enable efficient peptide desalting. In addition, proteins containing multiple disulfide 
bonds, such as antibodies, are resistant to proteolytic digestion. Currently our lab is working to 
resolve this issue by incorporating tris(2-carboxyethyl)phosphine (TCEP) coupled to agarose 
beads prior to the digestion chamber.  
Targeting both tau and Aβ can be more effective as an AD treatment therapy. 
Unsurprisingly, a subset of the six compounds from Treventis (Chapter 4) have dual inhibition 
effects on both tau and Aβ aggregates. Hence, it would be interesting to probe the structural 
effect of the inhibition mechanism on both proteins simultaneously as well as determining their 
epitope sites using TR-HDX. By doing so, rational design of more potent drug inhibitors could 
be achieved by targeting these common epitopes. Furthermore, it will also be interesting to 
conduct the same set of experiments in Chapter 4 using hyperphosphorylated tau as it represents 
one of the hallmarks of AD. Recently, a study conducted by Meier et al. demonstrated that 
hyperphosphorylated tau associates more closely to ribosomes in AD patients’ brain than the 
controls, leading to a decrease in RNA translation235. This aberrant tau-ribosomal interaction 
impaired protein synthesis which subsequently resulted in reduction of proteins that are involved 
in synaptic plasticity235. From a structural perspective, the exact mechanism of how 
hyperphosphorylated tau stalls the protein synthesis remain elusive. Hence, it would be 
interesting to use TR-HDX to study the structural factors behind how these interactions promote 
neuronal damage.  
The ultimate goal is to achieve high-throughput TR-HDX from a whole cell lysate, 
however challenges such as occurrence of isobaric peptides from different sets of proteins can 
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hinder the HDX analysis. This can potentially be resolved by incorporating the aforementioned 
optimised dimensions on the microfluidic chip. For example, deuterated proteins can be reduced 
and digested efficiently with subsequent online desalting on chip. DMS can then pre-filter 
complex peptide mixtures and confidently identify peptides using data independent acquisition 
(DIA) methodologies.  Upon knowing the protein contents in the lysate mixture, one can perform 
“targeted TR-HDX” on different sets of proteins. An example is to study the synergistic effect of 
both tau and Aβ in neuronal cells where one can monitor the conformational ensemble towards a 
pathogenic pathway or differences in conformations upon spiking with different inhibitor 
molecules or antibodies against pathogenic misfolded species.  
The DMS-HDX technique can also be extended to study structural characteristics of 
disease relevant p53 mutants. The majority of these mutations occur in the DNA binding region 
resulting in the perturbation of essential DNA interactions.  Furthermore, these mutants are 
highly unstable and unfold easily even at body temperatures 236. Hence it would be interesting to 
probe the structural features of different p53 mutants using the characteristics of DMS-HDX 
profiles. Although the results generated provide a global picture, DMS-HDX can perform a high-
throughput qualitative assay to filter out ineffective drugs during the drug development stages.  
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Figure A1. MS/MS spectra for phosphopeptides encompassing phosphorylation at residues Ser6, 
Ser15, Thr18, Ser20, Ser37, and S46 
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Appendix B: Supplementary informations for chapter 3 
 
Table B1. Proteolytic peptides resulting from native and hyperphosphorylated tau along with 
their associated PF. Adapted from Zhu et al70. 
Native Hyperphosphorylated* 
Peptide PF Peptide PF 
(A)/EPRQEF/(E)3-8 6.4±2.9 (A)/EPRQE/(F) 3-7 1.2±0.3 
(R)KDQGGYTMHQDQ/(E) 24-35 4.9±1.2 (Q)/EFEVME/(D) 7-12 2.6±0.6 
(R)KDQGGY/(T) 24-29 70.0±7 (L)/GDRKD(Q) 21-25 1.3±0.12 
(M)HQDQEGDT(D) 32-39 3.6±0.9 (T)MHQDQE/(G) 31-36 1.4±0.13 
(E)/GDTDAGLKESPLQT(P) 37-50  2.7±0.5 (Q)/DQEGDTDAGLKE/(S) 34-45 2.7±0.6 
(D)AGLKESP(L) 41-47 1.7±0.2 (D)AGLK(E) 41-44 1.6±0.15 
(L)/QTPTE/(D)49-53 69.0±7 (E)/SPLQ/(T) 46-49 1.2±0.2 
(E)/AAALIGDEPLENYLDTE/(Y) 56-
72 
5.4±2.3 (G)SEEPGSE/(T) 56-62 1.4±0.07 
(S)EEPGSETSDAK(S)57-67 3.0±0.8 (E)/TSDAKS(T) 63-68 3.2±0.4 
(E)/TSDA/(K) 63-66 1.9±0.3 (A)/KSTpPTAEDVTAPL/(V) 67-79 PHOS  2.7±0.05 
(T)AEDVTAP(L) 72-78 1.3±0.13 (P)TAED(V) 71-74 1.0+0.02 
(A)/PLVDEGAPGKQAAAQPHTE/(I)7
8-96 
7.0±2.33 (T)AEDVTAP(L) 72-78 1.0±0.07 
(L)/VDEGAP(G)80-85 10.0±1.6 (Q)/AAAQ/(P) 89-92 1.1±0.05 
(V)DEGAPG(K) 81-86 7.4±0.25 (A)/QPHTEIPEGTTAEEA/(G) 92-106 1.1±0.05 
(K)QAAAQPHTEIPEGT(T)88-101 1.5±0.2 (H)TEIP(E) 95-98 1.1±0.1 
(K)QAAAQP(H) 88-93 1.2±0.16 (E)/IPEGTTAEE/(A) 97-105   1.6±0.5 
(Q)/AAAQ/(P) 89-92 1.0±0.1 (G)TTAEEA/(G) 101-106 4.2±1.4 
(Q)/PHTEIP(E)93-98 3.2±0.21 (E)/AGIGD(T) 106-110   2.1±0.2 
(H)TEIP(E) 95-98 3.0±0.47 (E)/DEAA/(G) 116-119 2.5±0.01 
(E)/IPEGTTAEEA/(G)97-106 66.1±6.6 (A)/GHVTQ/(A) 120-124  7.9±0.6 
(A)/EEAGIGDTPSL/(E) 104-114  23.3±5.6 (V)SKSKD(G) 129-133 2.3±0.8 
(L)/EDEA/(A)115-118 1.3±0.18 (S)KSKDGT(G) 130-135 3.4±0.37 
(A)/GHVTQ/(A) 120-124  2.5±0.6 (G)SDDK(K) 137-140 2.3±0.5 
(G)SDDK(K)137-140 1.6±0.04 (K)KAKGADG(K) 141-147 1.4±0.15 
(D)DKKAKG(A)139-144 3.3+0.9 (K)KAKGADGKT(K) 141-149 1.0±0.12 
(D)KKAK(G)140-143  1.9±0.26 (A)/DGKT(K) 146-149 2.4±0.18 
(I)ATPRGAAP(P) 152-159 11.7±0.8 (A)/DGKTpKIATPRGAA/(P) 146-158 PHOS 3.0±0.3 
(A)/TPRGA/(A) 153-157   2.3±0.45 (A)/TpPRGAA/(P) 153-158 PHOS 2.4±0.18 
(A)/APPGQK(G)158-163 2.8±0.5 (T)RIPAKTp?PPAPKTp?P(P) 170-182 PHOS  2.2±0.25 
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(A)/APPGQKGQ/(A)158-165 7.8±0.3 (A)/KTp?PPAPKTp?PPSSpGEPPKSGD 
RSp?GYSp?SpPGSp?(P) 174-202 (PHOS 4X) 
1.9±0.25 
(P)PGQKGQA/(N) 160-166  10.1+1 (P)APKTPPSS(G) 178-185 3.1±0.16 
/KGQA/(N) 163-166 1.1±0.1 (G)YSSP(G) 197-200 4.1±0.1 
(Q)/KGQANATRIPA/(K)163-173 8.8±1.8 (P)GSpPG(T) 201-204 PHOS  3.0±0.23 
(P)APKTPPSS(G)178-185 8.8±0.42 (S)PGTP(G) 203-206  2.4±0.07 
(P)SSGEPPKSGDRSGY/(S) 184-197   5.4±1.5 (S)PGTPG(S) 203-207 1.3±0.16 
(E)/PPKSGDRSGYSSPG(S) 188-201   4.4±0.9 (T)PGSRSRTPSL/(P) 206-215 1.7±0.29 
(Y)/SSPGSPGTPGSRSRT(P)198-212  6.4±2 (R)TPSpL/(P) 212-215 PHOS 4.0±0.04 
(G)TPGSRSRTPSLPTP(P)205-218 3.8±0.8 (P)SpLPT(P) 214-217 PHOS  3.6±0.8 
(R)EPKKV(A)222-226  2.1+0.5 (P)TPPT(R) 217-220 2.1±0.4 
(K)KVAV(V) 225-228 2.0±0.4 (P)TpPPTp?REPKKVAVVRTpPPKSp?P 
Sp?SAKSp?R(L) 217-242 (PHOS 3X) 
1.3±0.16 
(K)VAVVRTPPKSPSS(A)226-238  3.7±1.2 (T)PPKSP(S) 232-236  3.0±0.15 
(V)AVVRTPP(K) 227-233 2.3±0.02 (S)PSSAKSRLQTA/(P) 236-246   3.0±0.13 
(V)AVVRT(P) 227-231  7.0+0.03 (A)/KSRL/(Q) 240-243  2.7±0.1 
(A)/KSRL/(Q) 240-243  4.9±1 (Q)/PGGGK(V) 270-274 2.5±0.3 
(A)/KSRLQ/(T)240-244  4.4±0.02 (I)INKK(L) 278-281 6.3±1.5 
(K)NVKSKIG(S) 255-261  2.4±0.1 (K)HVPGGGS(V) 299-305   1.3±0.18 
(K)SKIG(S)258-261 1.8±0.7 (K)HVPGGGSpV(Q) 299-306 PHOS 1.0±0.07 
(K)HQPGGGKVQII(N)268-278  7.8±3 (K)PVDLSKVTSKCG(S) 312-323 2.3±0.19 
(G)GKVQ/(I) 273-276  3.4±0.38 (L)/GNIHHKPGGGQ/(V) 326-336  4.2±0.75 
(S)NVQSKCGSKD(N) 286-295 35.2±3.5 (L)/DFK(D) 345-347  3.6±1.6 
(K)HVPGGGSVQIV(Y)299-309 6.5±0.8 (D)RVQSp(K) 349-352 PHOS  11.0±2.3 
(P)VDLSKVTS(K)313-320  4.9±0.03 (I)GSLDNI(T) 355-360 1.1±0.04 
(P)VDLSK(V) 313-317 5.8±0.03 (V)PGGGN(K) 364-368  4.7±1.8 
(P)VDLSKV(T)313-318  5.0+0.2 (E)/TpHKL/(T) 373-376 PHOS  1.4±0.02 
(L)/GNIHHKPGGGQVEVKSE/(K)326-
342 
2.0+0.24 (L)/TFRE/(N) 377-380  3.0±0.37 
(Q)/VEVKS(E)337-341 1.1+0.1 (T)FRENA/(K) 378-382  2.9±0.45 
(E)/VKSEK(L) 339-343 1.6+0.2 (E)/NAKA/(K) 381-384  5.0±0.25 
(K)IGSLDN(I) 354-359 17.5±0.2 (T)DHGAEIV(Y) 387-393 2.8±0.3 
(S)LDNITHV(P)357-363 23.3±0.2 (Y)/KSp?PVVSp?(G) 395-400 PHOS  1.4±0.09 
(N)ITH(V)360-362  1.7±0.3 (S)GDTSpPR(H) 401-406 PHOS  1.7±0.28 
(I)THVP(G) 361-364  1.7±0.3 (S)STGSI(D) 413-417 1.7±0.22 
(G)GGNKKIETH(K)366-374  1.8±0.3 (G)SIDMV(D) 416-420 2.0±0.12 
(G)NKKI(E) 368-371 1.1±0.1 (S)IDMVD(S) 417-421 2.6±0.04 
(N)KKIET(H) 369-373   2.0±0.4 (Q)/LATLADEVSASL/(A) 425-436 3.4±0.28 
(E)/THKLTF/(R) 373-378  1.9±0.3 (L)/ATLA/(D) 426-429 1.0±0.02 
(V)YKSP(V)394-397 1.5±0.2 (L)/ATLADEVSA/(S) 426-434  1.5±0.23 
(P)VVSGDTSPRHLSNV(S) 398-411  2.3±0.25 (L)/ADEVSASLAKQGL 429-441   1.8±0.06 
(P)VVSGDTSPRHLSNVSSTGSI 
D(M)398-418 
4.6±2 (A)/DEVSA/(S) 430-434 1.6±0.13 
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 * Ambiguous phosphorylation sites are marked (X)p? that could not be conclusively 
identified by MS/MS. Multiple phosphorylation sites are labeled as (PHOS nX) where n 
represents the number of phosphorylations on the observed peptide.  
 
(H)LSNVSSTGSIDM(V) 408-419 2.8±0.17 (E)/VSASL/(A) 432-436   1.8±0.12 
(L)/SNVSSTGS(I) 409-416  5.4±0.32 (E)/VSASLA/(K) 432-437  4.7±1.4 
(D)SPQLATLADE/(V) 422-431 1.5±0.3 (L)/AKQGL 437-441   2.5±0.03 
(T)LADEVSASLAKQGL 428-441  17.5±0.9   
(L)/ADEVSASLAKQGL 429-441   9.4±0.5   
(E)/VSASLA/(K) 432-437   10.1±1   
(A)/SLAKQGL 435-441  11.7±2   
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Figure B1. MS/MS spectra for phosphorylated tau peptides. Adapted from Zhu et al70. 
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Figure B2. Denaturing SDS gel showing shift of phosphorylated tau (5 and 30 hours incubations) 
to higher mass. Adapted from Zhu et al70. 
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Figure B3. TEM image of PHF at 56 hours after tau hyperphosphorylation. Adapted from Zhu et 
al70. 
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Appendix C: Supplementary informations for chapter 4 
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Figure C1. (Left) IC50 value deduced from triplicate ELISA runs (each colour represents a single 
run). (Right) Silver staining gel. Negative and positive signs represent negative and positive 
control lanes respectively and adjacent lanes show the protein/aggregate migration lanes with 
their corresponding spiked drug concentrations in µM. The data was provided by Treventis. 
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Appendix D: Supplementary informations for chapter 5 
 
 
 
Figure D1: DMS ionograms of cytochrome c, myoglobin, native tau, and phosphotau under 
influences of different modifier gas conditions. Adapted from Zhu et al228. 
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Figure D2: DMS-HDX profiles using labeling through resolution gas only. In panel A, native cytochrome 
c is labeled with D2O. Charge states, +9 (filled circle), +10 (grey circle), and +11 (filled grey square) are 
illustrated. In panel B, unfolded cytochrome c is labeled with D2O. Charge states +8 (filled circle), +9 
(grey circle) and +10 (filled grey square) are illustrated. In panel C, phosphotau is labeled with ND4OD. 
Charge states +36 (filled circle), +38 (grey circle), and +40 (filled grey square) are shown. Adapted from 
Zhu et al228. 
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Figure D3: Mass spectrum of native myoglobin with insets showing DMS-HDX profiles of 
respective charge states labeled using modifier gas ND4OD:MeOD and throttle gas ND4OD. 
Adapted from Zhu et al228. 
 
 
